

CURRICULUM VITAE

Date of Revision: May 2, 2024

Name: Sandra Ann Springer, M.D.

Current title: Professor of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, Clinician Scientist Track, Yale School of Medicine, with a Secondary Appointment in the Yale School of Nursing as Clinical Professor of Nursing

Term: Continuing appointment beginning July 1, 2022

School: Yale School of Medicine

Education:
A.B. Harvard University (Psychology) 1990
M.D. University of Massachusetts Medical School 1998

Career/Academic Appointments:

1998-1999	Intern, Internal Medicine, Yale-New Haven Hospital, New Haven, CT
1999-2001	Resident, Internal Medicine, Yale-New Haven Hospital, New Haven, CT
2001-2004	Fellow, Infectious Disease, Yale University School of Medicine, New Haven, CT
2004-2008	Clinical Instructor, Department of Medicine, Section of Infectious Disease, Yale School of Medicine, New Haven, CT
2008-2014	Assistant Professor of Medicine, Department of Medicine, Section of Infectious Disease, Yale School of Medicine, New Haven, CT
2009-Present:	Attending Physician, Department of Internal Medicine, Section of Infectious Disease, Veterans Administration Connecticut Healthcare System (VACHS)
2014-Present:	Associate Professor of Medicine, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine
2014-Present:	Associate Clinical Professor of Nursing, Yale School of Nursing
2017-2018:	Physician APT Foundation, Inc.
2022- Present:	Professor of Medicine, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, CT * July 1, 2022
2023- Present:	Clinical Professor of Nursing, Yale School of Nursing

Administrative Positions:

2007-2010	Medical Director of Project CONNECT and Project BRIDGE, Yale University Clinical and Community Research, Yale AIDS Program, New Haven, CT
2009- Present	Core Research Scientist, Center for Interdisciplinary Research on AIDS (CIRA), Clinical Services Core, Yale School of Medicine and Yale School of Public Health
2009–Present	Director, Infectious Diseases Clinic, Veterans Administration Connecticut Healthcare System, Newington Site.
2018- 2020	Vice President of the Connecticut Academy of Arts and Sciences (CAAS)
2019- Present	Director of InSTRIDE –Integrating Substance Use Treatment Research with Infectious Disease for Everyone https://medicine.yale.edu/lab/springer/
2020- Present	NIDA JCOIN LEAP Scholars Program Co-leader
2021-Present	Appointed International Antiviral Society–USA (IAS–USA) Antiretroviral Guidelines Panel Member (December 16, 2021) *
2023- Present	Core Faculty for IAS-USA, appointed June 8, 2023.

Board Certification:

American Board of Internal Medicine, Internal Medicine, 2001 & 2011
American Board of Infectious Diseases, 2005, 2015
American Board of Addiction Medicine, 2010

Professional Honors & Recognition:

International/National/Regional/Local

2023 Awarded the Vizient Pharmacy Vision Award for Excellence In Public Policy: Yale New Haven Health system, individuals: Osama Abdelghany, Jacqueline Blake, Cynthia Frank, Marjorie Lazarre, LeeAnn Miller, Prashant Patel, Sandra Springer. August 18, 2023.

2023- Present: Received Acceptance into the Johns Hopkins Carey Business School Innovations for Substance Use Disorders (I4SUD) NIDA funded Program (August 28, 2023-October 20, 2023) Mission to train researchers to develop innovative interventions to solve challenges related to SUDs.

2023- Present: Appointed to the National Academies of Sciences, Engineering, and Medicine's Committee on Framework for the Consideration of Chronic Conditions in Women

2022-2023: Committee member with Viaduct and Pew Charitable Trusts to *Develop Medicaid standards of care for Opioid Use Disorder in correctional facilities.*

2021-Present: Appointed International Antiviral Society–USA (IAS–USA) Antiretroviral Guidelines Panel Member (December 16, 2021) *

2021-Present: Appointed Committee Member for Guidelines for Withdrawal management in Jails as part of collaboration between American Society of Addiction Medicine (ASAM), the National Commission on Correctional Health Care (NCCHC) and the Department of Justice /Bureau of Justice Agency (BJA).

2021- Present: Invited Appointed member of American Society of Addiction Medicine (ASAM) Criminal Justice Guideline Committee (CJGC)

2019- Present Invited Member of the NIAAA/NIDA Interagency Work Group on Drinking and Drug Use in Women and Girls

2019 –2020: Appointed to the National Academies of Sciences, Engineering, and Medicine's Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs

2018 –2020: Invited member of the American Society of Addiction Medicine (ASAM)'s National Practice Guideline Expert Panel for Medication Treatment for OUD

2018- Present: Invited Provider in the SAMHSA STR-TA Consortium to provide assistance to clinicians in the community to treat opioid use disorder

2018- 2020: Invited Vice President of the Connecticut Academy of Arts & Sciences (CAAS)

2018: Invited Planning Committee Member of the *National Academies of Sciences, Engineering and Medicine* (NASEM) Workshop 'Integrating Infectious Disease Considerations with Response to the Opioid Epidemic'

2017-2020: Invited Member of the IDSA and HIVMA Working Group on Infectious Disease Issues In the Opioid Epidemic

2018: Renewed National Institute of Drug Abuse Independent Scientist Award K02

2015- Present: Active member of Standing NIDA review committee for K99, K12 and T32 Grants

2014-2019: Member of NIDA's Seek Test Treat and Retain Consortium (STTR)

2014-2019: Co-chair of NIDA's Seek Test Treat And Retain Committee on HIV Risk Behavior Data Harmonization

2011: National Institute of Drug Abuse Independent Scientist Award K02

2010: Invited Member of the Seek, Test, Treat and Retain Criminal Justice and HIV Modeling Group (STTR CJS), Sponsored by National Institute on Drug Abuse (NIDA)

2007: VNA-South Central Partnership Award for Outstanding Provider in the Community "that best exemplifies the mission of their organization and recognizes the integral part that nursing plays to the health care team".

2006: Recipient of the 2006 B. Jaye Anno Award of Excellence in Communication for:

Altice FL, Springer SA. 'Overview of HIV Care and Antiretroviral.' Clinical Practice in Correctional Medicine, 2nd edition. Puissis M. ed. Elsevier Inc. San Diego, CA. 2005
2005: National Institute of Drug Abuse K23 Mentored Career Development Award
2002: Bristol-Myers Squibb HIV Virology Fellowship Award
1998: Academic Excellence Award for Women in Field of Medicine: University of Massachusetts Medical School

Grant/Clinical Trials History:

Current Grants

Agency: NIDA

I.D.#: DP1DA056106-01 (**Avant Garde Award**)

Title: Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live

P.I.: Sandra A. Springer, M.D.

Role on Project: Principal Investigator

Percent Effort: 35%

Direct costs per year: \$700,000

Total Costs per project Period: \$3,500,000

Project Period: 05/01/22-04/30/27

Agency: NIDA

ID#: 1U01DA053039-01

Title: Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations

PI: Sandra A. Springer, MD (contact), Kevin Knight, PhD, Ank Nijhawan, MD

Role on project: Principal Investigator (contact)

Percent effort: 9.33%

Direct costs per year: 2,194,299

Total costs per project period: \$11,113,030

Project Period: 09/30/2020-07/31/2025

Agency: NIDA

ID#: 1U01DA047982-01

Title: Long-acting buprenorphine vs. naltrexone opioid treatment in CJS-involved adults

PIs: Joshua Lee (contact), **Sandra Springer**, Robert Schwartz, David Farabee, Lisa Marsch, Elizabeth Waddell

Role on project: Principal Investigator

Percent Effort: 10%

Direct costs per year: \$389,100 (CT)

Total Costs per project period: \$17,761,647

Project Period: 08/01/19 – 04/30/24

Agency: NCATS

ID#: 1 U01 TR002763-01

Title: Coordinated medical treatment of opioid use disorder and infectious disease

P.I.: Sandra Springer (contact), Edward Nunes, Kathleen Brady, & Frances Levin

Role on project: Principal Investigator (contact)

Percent Effort: 7.58%

Direct Costs per year: \$1,170,094

Total Costs per project period: \$5,419,179
Project Period: 07/18/19-06/30/24

Agency: National Center for Complementary and Integrative Health
ID#: R61 AT010606

Title: Adapting the HOPE Online Support Intervention to Increase MAT Uptake Among OUD Patients
PI: Sean Young, MD and Sayers, UCI

Role On Project: Consultant

Project Period: 08/14/2019- 08/13/24

Agency: Veterans Affairs Cooperative Studies Program

Study ID#: Cooperative Study #2014 (CSP 2014)

Title: Comparative Effectiveness of Two Formulations of **B**uprenorphine for **T**reating Opioid Use Disorder in **V**eterans (**VA-BRAVE**)

P. I.: Sandra A. Springer & Ismene Petrakis

Role on Project: Principal Investigator

Percent effort: 20% (VA, has MOU with Yale; VA time: 0.6CM (5%))*

Total Costs per project period: \$40,922,630

Project Period: 03/31/19-03/30/25

* Dr. Springer has a MOU with the VA by which she dedicates 25% of her effort (Shown above)

Agency: NIDA

ID#: R61/R33 DA047037

Title: Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders.

P.I.: Sandra A. Springer (contact), Ya-Chi Ho, Yuval Kluger

Role on project: Principal Investigator (contact).

Percent Effort: 12.8 %

Direct Costs per year: \$500,605

Total costs per project period: \$3,920,900

Project Period: 09/1/18 – 8/30/24

Agency: NIH/NIDA

I.D. #: R01DA043337

Title: The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction

P.I.: Sandra A. Springer, M.D. (contact) & Albert Shaw, M.D. PhD

Role on project: Principal Investigator (contact)

Percent Effort: 1%

Direct Costs per year: \$685, 869

Total Costs for project period: \$5,756,801

Project Period: 9/1/16-5/31/21, *No cost Extension through 5/31/23

Past Grants

Agency: NIDA

I.D.#: 2K02DA032322

Title: Evaluations of medication assisted treatments for substance use disorders among persons living with and at risk for HIV infection

P.I. Sandra Springer, MD

Role on project: Principal Investigator

Percent Effort: 75%

Direct costs per year: \$114,665

Total Costs per project period: \$619,190

Project Period: 05/01/18-05/02/22

Agency: NIAAA

ID#: R01AA027976

PI: (Braithwaite, S)

Title: From 90-90-90 to 95-95-95 and beyond: Optimizing and targeting combination HIV prevention for Zimbabwe, eSwatini, and Kwazulu Natal

Role on project: Co-investigator

Percent effort: 1%

Direct costs per year: for CT \$65,617

Total Costs per project period for CT: \$420,120

Project Period: 10/01/19 – 05/02/22

Agency: NIAAA

ID#: R01 18-005067

PI: Scott Braithwaite, MD

Role on project: Co-investigator

Title: Could long-acting medications facilitate ‘ending AIDS by 2030’ in southern Africa?)

Role on project: Co-Investigator

Percent effort: 1%

Direct Costs per year: \$50,623

Project Period: 10/1/19 – 05/02/22

Agency: NIDA

Study ID: 1 UM1 DA049415-01

Title: CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State

P.I.: El-Bassel N, Feaster D, Gilbert L, Nunes E

Role on project: co-investigator

Percent Effort: 1% (concurrent with K02)

Direct cost per year project overall: \$12,346,892

Total Costs project overall: \$49,387,568

Direct costs per year for CT: \$50,497

Total costs per project period for CT: \$267,060

Project Period: 04/17/19-05/02/22

Agency: NIH/NIDA

I.D. # R01 DA033679

Title: Expanding Medication Assisted Therapies (MAT) in Ukraine

P.I.: Frederick L. Altice, M.D.

Role on project: Co-Investigator

Percent Effort: 10%

Direct cost per year: Year 1: \$445,311

Total Costs for project period: \$2,800,746

Project Period: 04/15/12-03/31/17

Agency: NIH/NIDA

I.D.# R01 DA030762-S1

Title: Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations, Administrative Supplement

P.I.: Sandra A. Springer, MD

Role on project: Principal Investigator

Percent effort: 10%

Direct costs: \$90,000

Project Period: **9/1/15 – 8/31/16**

Agency: NIH/NIDA

I.D. #: K02 DA032322

Title: Mediation Assisted Therapy as a Conduit to Care for HIV+ CJ Populations Transitioning to the Community

PI: Sandra A. Springer, MD

Role on project: Principal Investigator

Percent Effort: 60%

Direct cost per year: Year 1 Direct Costs: \$142,810

Total costs for project period: \$771,175

Project Period: 07/01/11-06/30/16

Agency: NIH/NIDA

I.D. #: R01 DA030762

Title: Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations

P.I: Sandra A. Springer, M.D.

Role on project: Principal Investigator

Percent Effort: 15%

Direct costs per year: Year 1 Direct Cost: \$507,647

Total costs for project period: \$4,213,201

Project Period: 09/30/10 – 03/31/16

Agency: NIH/NIDA

I.D. #: R01DA030768

Title: HIV, Buprenorphine, and the Criminal Justice System

P.I. Frederick L. Altice, M.D.

Role on project: Co-Investigator

Percent Effort: 5%

Direct costs per year: Year 1 Direct Cost: \$363,311

Total costs for project period: \$3,797,572

Project Period: 09/30/10 – 06/30/16

Agency: NIH/NIAAA

I.D. #: R01 AA018944

Title: Alcohol Pharmacotherapies among Released Prisoners.

P.I.: Sandra A. Springer, MD (contact) & Frederick L. Altice, M.D.

Role on project: Principal Investigator

Percent Effort: 15%

Direct costs per year: Year 1 Direct Cost: \$459,232

Total costs for project period: \$4,457,484

Project Period: 09/30/09 – 08/31/15

Agency: NIH/NIDA

I.D. #: K23 DA 019381

P.I: Sandra A. Springer, M.D.

Title: Opiate Dependence, HIV and Adherence Interventions

PI: Sandra A. Springer, MD
Role on Project: Principal Investigator
Percent Effort: 80%
Total Costs for Project period: \$873,520
Project Period: 09/01/05-09/01/10

Agency: NIH/NIDA
I.D. #: R01 DA17059
Title: Project CONNECT: Directly Observed Therapy for Community-Released HIV+ Prisoners
P.I.: Frederick L. Altice, M.D.
Role on project: Medical Director, Co-Investigator
Percent Effort: 50%
Total Costs for Project Period: \$3,358,983
Project Period: 09/01/04-06/30/09

Agency: NIH/NIDA
I.D.#: R21 DA019843
Title: Improving Health Outcomes for Released HIV+ Prisoners
P.I.: Frederick L. Altice, M.D.
Role on Project: Project Medical Director/Co-investigator
Percent Effort: 50%
Total Costs for Project Period: \$600,000
Project Period: 09/01/05-09/01/07

Agency: Bristol Myers Squibb
Title: The Evaluation of Antiretroviral Treatment among HIV+ Prisoners in a Correctional Setting
PI: Sandra A. Springer, MD
Role on Project: Principal Investigator
Percent Effort: 80%
Total award cost: \$10,000
Project Period: 07/01/03-06/30/04

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale

International/National

- 2024: Invited speaker, Meiklejohn Lecture at University of Colorado School of Medicine, Department of Medicine Grand Rounds, May 22, 2024, Denver, CO.
- 2024: Invited speaker, University of Colorado School of Medicine, General Internal Medicine, Grand Rounds, May 21, 2024, Denver, CO.
- 2024 Invited Speaker, Brown, Tufts & Boston University Center for AIDS Research (CFAR). Keynote speaker. May 10, 2024. Providence, RI.
- 2024: Invited Speaker *The IAS-USA Annual Update on HIV Management in Atlanta, Georgia*. Co-chaired by Jeffrey L. Lennox, MD, and Michael S. Saag, MD April 18, 2024. In-person. **“Substance Use Disorder and HIV.”**

- 2024: Invited Speaker *The IAS-USA Annual Update on HIV Management in New York City, NY*. Co-chaired by Elaine Abrams, MD, and Raphael Landovitz, MD on March 18, 2024. In-person. **“Substance Use Disorder and HIV.”**
- 2024: Invited Speaker, Medical University of South Carolina, February 20, 2024. Integration of Addiction and HIV treatment and Prevention.
- 2024: Invited Speaker , **NIDA HIV seminar**, Integrating Addiction and HIV prevention and Treatment and Bringing it to Where People Live. January 24, 2024. Live virtual lecture.
- 2023: National Institutes of Health (NIH) sponsored virtual meeting titled, **“Pharmacy-Centered HIV Research: Current Landscape and Future Frontiers**. June 28-29, 2023. Invited Speaker: ‘Advancing mobile pharmacies to deliver PrEP/ART, buprenorphine and naloxone to people who use drugs in Connecticut,’ June 29, 2023.
- 2023: Invited Speaker, University of California San Diego HIV and Global Health Rounds. Integration of Opioid Use Disorder treatment with Infectious Disease: it is not just the smart thing to, but also the right thing to do! June 9, 2023
- 2023: Invited Speaker for the [Impact of Health & Justice Research on Policy & Practice Conference hosted by the Institute of Behavioral Research at Texas Christian University](#). April 17, 2023
- 2023: Invited Speaker *The IAS-USA Annual Update on HIV Management in Atlanta, Georgia*. Co-chaired by Jeffrey L. Lennox, MD, and Michael S. Saag, MD Friday, March 31, 2023. In-person with no virtual component. I was invited for a presentation on **“Substance Use Disorder and HIV.”**
- 2023: Invited Speaker *The IAS-USA Annual Update on HIV Management in New York City, NY*. Co-chaired by Elaine Abrams, MD, and Paul Volberding, MD March 16, 2023. In-person with no virtual component. I was invited for a presentation on **“Substance Use Disorder and HIV.”**
- 2023: Invited speaker, Center for Technology and Behavioral Health, Dartmouth College. January 30, 2023. “Integration of Addiction and Infectious Disease Prevention and treatment Interventions”. In person.
- 2023: Invited speaker, Paul J. Galkin Memorial Lectureship Series, Hosted by the Miriam Hospitals Department of Medicine, Section of Infectious Disease, Brown School of Medicine. January 23, 2023. “Integration of Addiction and Infectious Disease Prevention and Treatment Interventions is Not Only Smart, It Is the Right Thing to Do!”
- 2022: Invited Speaker: Virtual Update on the Latest IAS-USA Guidelines for the treatment and Prevention of HIV infection in adults. December 15, 2022, Live Webinar, 1-5pm. Dr. Springer was a member of the panel and co-led a presentation on ‘Substance Use Disorders in Adults with HIV or at risk for HIV’.
- 2022: Invited Speaker: Opioid Response Network (ORN), New England Regional Office. Screening, Diagnosis & Treatment of Opioid Use Disorder. October 13, 2022. Live Webinar.
- 2022: Invited Speaker: NIDA, Justice Collaborative Opioid Initiative Network (JCOIN). Mobile Health Unit experience for provision of PrEP, HIV treatment and medication treatment for OUD for justice involved persons: Lessons Learned. September 19, 2022.

- 2022: Invited speaker Health Services Advisory Group (HSAG) for States of Arizona and California Opioid Stewardship Program (OSP), Screening Patients for Opioid Use Disorder Risk and Opioid Withdrawal, January 13, 2022.
- 2021: Invited Grand Rounds Speaker, University of Rochester School of Medicine, Department of Medicine: Integration of Opioid Addiction and HIV prevention and treatment is Key to Achieving the Goals of the National Ending the HIV Epidemic Plan. July 1, 2021
- 2021: Invited Grand Rounds Speaker, Oregon Health Sciences University, Department of Medicine: ‘Yes in My Backyard’ for Integration of Opioid Addiction Treatment with Infectious disease Prevention and Treatment. June 1, 2021
- 2021: Invited Speaker Ohio State University School of Medicine’s Medical Scientist Training Program. “Integration of infectious disease and opioid use disorder treatment is not only smart but the right thing to do!” February 4, 2021.
- 2020: Invited Speaker by NIAAA/NIDA Interagency Work Group on Drinking and Drug Use in Women and Girls: “*Medication treatment for Addiction and HIV improves Outcomes Upon Release to the Community for Criminal Justice Involved Persons.*” November 20, 2020.
- 2020: Invited Speaker by IDSA for IDWeek 2020. *Our Most Challenge Cases: Impact of COVID-19 on People with HIV and Substance Use Disorders.* October 24, 2020.
- 2020: Invited Speaker by NIDA: *Addressing risk Through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations* (Springer SA, contact PI) (JCOIN / HIV 042 grant). September 29, 2020.
- 2020: Invited Presenter. THE AMERICAN SOCIETY OF ADDICTION MEDICINE (ASAM) NATIONAL PRACTICE GUIDELINE FOR THE TREATMENT OF OPIOID USE DISORDER: 2020 FOCUSED UPDATE WEBINAR for INDIVIDUALS IN THE CRIMINAL JUSTICE SYSTEM. September 8, 2020
- 2020: Invited speaker SUNY Downstate Medical Center’s HIV/ID Research Seminar. *Preventing HIV Outbreaks among People who Inject Drugs in the United States: Integration of opioid and infectious disease prevention and treatment is critical.* October 15, 2020.
- 2020: Invited Speaker at the Center for Drug Use and HIV Research, New York University. *Integration of Opioid Use Disorder and Infectious Disease Prevention and Treatment: Not only smart but the right thing to do!* June 9, 2020.
- 2020: Invited Speaker to the O’Neill Institute for National and Global Health Law, Georgetown University Law Center “Promoting the Health of People Who Use Drugs on the Path to Ending the HIV Epidemic.” A convening of the HIV Policy Project. February 19, 2020
- 2019: Invited Speaker for the Connecticut Pharmacist Association, December Continuing Education Program in Bristol CT: Alcohol Use disorders. December 10, 2019
- 2019: Invited Speaker National Institute of Alcohol Abuse and Alcoholism (NIAAA) Workshop entitled: *Advancing Uptake, Retention, and Adherence to Antiretroviral Therapy and to Pre-Exposure Prophylaxis (PrEP) for HIV/AIDS Prevention among Alcohol-Using Populations*” workshop September 23-24, 2019. NIH. Bethesda, MD
- 2019: Invited speaker by National Institute of Drug Abuse (NIDA) to members of NIDA: “*The Opioid and Associated HIV Epidemics: Why Understanding Sex and Gender Differences in*

Medication Treatments for OUD Matters". April 30, 2019. Bethesda, MD

- 2019: Invited speaker: Johns Hopkins Bloomberg School of Public Health. Johns Hopkins CFAR Adolescent and Young Adults Scientific Working Group (AYA SWG) 4th Annual Spring Symposium: "*HIV/STIs, Substance Use, and the Criminal Justice System... Missed Opportunities for Prevention and Treatment*". April 23, 2019.
- 2019: Invited Speaker: National Institutes of Alcohol Abuse and Alcoholism (NIAAA) U13 Alcohol Behavioral HIV Prevention Research: Mechanisms and Intervention Development Conference Program. Discussant of "*Extension of alcohol challenge studies to investigate mechanisms underlying the association between alcohol consumption, ART adherence, and PrEP uptake*". January 29-30, 2019. Bethesda, MD.
- 2018: Invited Speaker for the 2018 National Center for AIDS Research (CFAR) Scientific Symposium, *From Bench to Bedside to Our Own Backyard: Celebrating 20 Years of the CFAR at Emory University School of Public Health*, on Thursday, November 8, 2018. Session: "Tackling Syndemics: Identifying Solutions to the Persistent Crisis of Substance Abuse & HIV."
- 2018: Invited Planning Working Group Member, Moderator and Speaker for the *National Academies of Sciences Engineering and Medicine (NASEM) Workshop on Integrating Infectious Disease Considerations with Response to the Opioid Epidemic* convened on March 12-13, 2018. Washington, DC.
http://nationalacademies.org/hmd/Activities/PublicHealth/IntegratingInfectiousDiseaseConsiderationswithResponsetotheOpioidEpidemic/2018_MAR-12.aspx.
- 2017: Invited Speaker by New England Association of Drug Court Professionals for Conference: *The Drug Courts: Where Justice and Treatment Meet - Strengthening Community Connections-Conference*. Workshop on medication assisted treatment for opioid use disorder and other Medical Issues within the Criminal Justice System; and a second lecture: Medication Assisted Treatment for the Criminal Justice Population in Drug/Specialty Courts. New England Association of Drug Court Professionals (NEADCP). November 29, 2017. Marlborough, MA
- 2017: Invited Speaker by the Women Drinking and Pregnancy Work Group of Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (WDP/ICCFASD), National Institute of Alcohol Abuse and Alcoholism (NIAAA). National Conference on Alcohol and Other Substance Use Among Women and Girls. October 26-27, 2017. Washington, DC
- 2017: Invited Speaker for Connecticut Pharmacists CME : Title of my talk: An Overview of Medication Assisted Therapies for the Treatment of Opioid Use Disorder. Fall Connecticut Pharmacists Association Continuing Education Program. October 18, 2017. Farmington, CT.
- 2017: Invited Speaker by HIV diagnostics and treatment at the Healthcare Committee Of the Saint Petersburg Government and the Saint Petersburg Center for Prevention and Control of AIDS and Infectious. Scientific conference: 'Modern Aspects of Prevention, Diagnostics and Treatment of HIV'. October 5-6, 2017. St. Petersburg, Russia.
- 2017: Invited Speaker by Office of Women's Healthy, U.S. Department of Health and Human Services. 'Women and Girls Don't Live in Silos: Integrating HIV/AIDS, Substance Use Disorder & Reproductive Health Screening & Treatment Methods'. Webinar March 16, 2017.
- 2016: Invited speaker, 9th Annual International Women's Conference: Drug treatment as HIV prevention among women who use drugs. Palm Springs, CA, June 10, 2016.

- 2016: Invited speaker, SAMHSA and NIDA, Non-agonist Treatments- Extended-release Naltrexone Summit, title: Extended-release naltrexone to improve HIV outcomes, at SAMHSA, Bethesda, MD, May 11, 2016.
- 2016: Invited Web-lecturer: SAMHSA. Drug treatment to improve the HIV continuum of care for Women who use drugs: progress, gaps and future directions, April 27, 2016
- 2015: Invited lecturer, Columbia School of Social Worker, Drug Treatment as HIV Prevention among Women and Girls who Inject Drugs from a Global Perspective: Progress, Gaps, and Future Direction. New York, NY. Journal of Acquired Immune Deficiencies (JAIDS) Special Issue Event. Sponsored by NIDA. Rethinking the Global Response to the HIV Epidemic Among Women Who Use Drugs: an Urgent Cal to Actions. Columbia School of Social Work. October 30, 2015.
- 2015: Invited Lecturer Alkermes Inc. Extended-release Naltrexone Summit meeting, Bethesda, MD, March 2015.
- 2015: Invited lecturer, Howard University. HIV Treatment among Persons with Alcohol and Opioid Use Disorders. June 9, 2015
- 2014: Invited Speaker, American Psychiatric Association (APA), HIV, substance use and mental illness. San Francisco, CA. November 2, 2014:
- 2014: Invited Speaker, National Institute of Drug Abuse (NIDA), Project NEW HOPE, Preliminary Results, September 15, 2014.
- 2013: Invited Speaker. National Institute of Drug Abuse (NIDA), Seek Test Treat and Retain (STTR) meeting, May 9-10, 2013, Bethesda, MD
- 2013: Invited Lecture. Brown University Center for AIDS Research (CFAR)/ Yale CIRA Collaborative Meeting; Invited lecturer “ Medication Assisted Therapy as a Conduit to care fro HIV+ Alcohol and Opioid Dependent Released Criminal Justice Populations”, Miriam Hospital, Providence, RI, January 25, 2013
- 2012: Invited Speaker, HIV and Corrections and Beyond Symposium, Organizer on Behalf of Center for Interdisciplinary Research on AIDS, XIX International AIDS Conference, Washington, D.C. July 22nd, 2012.
- 2011: Invited Speaker by NIDA and the International Workshop on Treatment as Prevention, (TasP), Vancouver, Canada. May 4-6, 2011.
- 2010: Invited Presenter, National Institute of Drug Abuse (NIDA), Seek Test Treat and Retain in the Criminal Justice System. Bethesda, MD.
- 2010: Invited Presenter by National Institute of Drug Abuse (NIDA), Substance Abuse Interventions as A Conduit to Care for HIV+ persons within the Criminal Justice System, at National Institute of Drug Abuse (NIDA), HIV, Technology and Adherence Symposium. Bethesda, MD.
- 2009: Invited Presenter, Alcohol Pharmacotherapies for HIV-infected Released Prisoners, National Institute on Alcoholism and Alcohol Abuse (NIAAA), Bethesda, MD.

Regional

- 2024: ‘The Criminal Justice System and its impact of HIV within the community’; Subspecialty Conf Greenwich Hospital, Greenwich, CT May 15, 2024
- 2024: Invited Speaker, Behavioral Health: Substance use Disorder at the 9th Yale Connecticut Course Mandates CME Symposium in-person, New Haven, CT on April 20, 2024
- 2023: Infectious Disease Fellowship Invited Lecture. Integrating Infectious Disease and Addiction Medicine: A Call to Action. June 7, 2023
- 2022: HIV prevention and Treatment. Danbury Internal Medicine Residency. September 29, 2022.
- 2022: HIV and Substance Use. Nathan Smith Clinic. Yale School of Medicine. September 6, 2022.
- 2022: CT Department of Public Health and NEAETC sponsored webinar: EHE Summit: Through a Syndemic Lens: Dr. Springer: Respond - Mental Health and Substance Use Disorder, Health Disparities. June 21, 2022, from 1:00pm to 4:00pm.
- 2021: New England AIDS Education and Training Center (NAETC) and the National Alliance for HIV Education and Workforce Development. May 11, 2021.
- 2021: New England AIDS Education and Training Center (NAETC) and the National Alliance for HIV Education and Workforce Development and the Opioid Response Network interactive webinar titled “Connecticut Response to the Triple Threat: HIV, HCV and Substance Use Disorder”. Long-acting Medication Treatments for Opioid Use Disorder: Potential implications to improve the HIV and HCV Cascades of Care. January 19, 2021
- 2020: VA Project ECHO. PrEP for persons who Use drugs. May 11, 2020.
- 2017: PrEP for persons with substance use disorders. VACHS Addiction Psychiatry Services. November 14, 2017.
- 2017: Medication assisted therapy for Opioid Use Disorder. National Committee of Pharmacists. Farmington, CT. October 28, 2017.
- 2017: VA PrEP for Veterans. Invited Speaker for Community Based Providers, VACHS. January 26, 2017.
- 2016: VA PRIME Center Invited Speaker. Extended-release naltrexone reduces alcohol consumption and maintains VL suppression among released prisoners living with HIV after release to the community: Results of a randomized controlled trial. November 14, 2016.
- 2016: Pre- Exposure Prophylaxis, Invited lecturer, VACHS, Primary Care Physicians, May 3, 2016.
- 2013: The use of Extended-Release Naltrexone to reduce drinking for DUI offenders, presented to CT department of Probation, Hartford, CT
- 2012: Extended-Release Naltrexone as a conduit to care for released criminal justice populations: Invited to present to Connecticut Department of Corrections, Hartford, CT.
- 2011: The Center for Translational Neuroscience of Alcoholism, West Haven, CT. Invited to present research on medication assisted therapy.
- 2010: Connecticut Department of Public Health AIDS & Chronic Diseases Section Invited to present "Substance abuse and HIV interactions"

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale

International/National

2024: **Sandra A. Springer**. Early Lessons Learned from a Multisite Hybrid Type 1 Effectiveness-Implementation Randomized Controlled Trial of Patient Navigation Compared to Mobile Health Unit Service Linkage to HIV Prevention and Treatment Services in the Community for Justice-Involved Persons. Oral presentation. XXXVIIIth International Academy of Law and Mental Health Conference. Barcelona, Spain July 22-26, 2024

2024: Alysse M. Schultheis, MA^a, Sheela Shenoi, MD, MPH^a, Angela DiPaola, PhD^a, Adati Tarfa, PharmD, MS, PhD^a, Cynthia Frank, PhD, RN^a, Osama Abdelghany, PharmD, MHA, BCOP^b, **Sandra A. Springer**, MD^{a,c}. Health on Wheels: The Mobile Pharmacy Clinic in Motion. Oral Presentation. 17th Annual ACCJH Conference. April 10 - 12, 2024 in Phoenix, Arizona.

2024: Rich Colon, **Sandra Springer**. Lessons Learned: How to Reach Justice Involved Persons with Mobile Health Units". 17th Annual ACCJH Conference. Oral Presentation. April 10 - 12, 2024 in Phoenix, Arizona.

2024: Ralph Brooks, **Sandra Springer**. "Efficient Data Collection: Building the Timeline Followback (TLFB) in REDCap". 17th Annual ACCJH Conference as a Lightning Talk. April 10 - 12, 2024 in Phoenix, Arizona.

2024: Ank Nijhawan, **Sandra Springer**. Hierarchy of Needs Among Justice-Involved Individuals Enrolled in ACTION Study". 17th Annual ACCJH Conference. Poster Presentation. April 10 - 12, 2024 in Phoenix, Arizona

2024: Ank Nijhawan, **Sandra Springer**. Prevalence of Opioid and Stimulant Use Disorders and Prior Receipt of Substance Use Disorder Treatment in the ACTION Study". 17th Annual ACCJH Conference. Poster Presentation. April 10 - 12, 2024 in Phoenix, Arizona.

2024: Sandra Springer, Manesh Gopolades, Michelle Strong, Alain Litwin, Frances Levin, Ned Nunes. Workshop entitled: Extended-Release Buprenorphine for Vulnerable Populations with Opioid Use Disorder: Clinical Challenges, Pharmacokinetics, and Outcomes. American Academy of Addiction Psychiatry Annual Meeting and Scientific Symposium. San Diego, CA. December 7-10, 2023.

2024: Proffitt, R.P., Pankow, J., Bennett, A., DeMoss, D., Scarborough, J.H., Kuo, I., Nijhawan, A., **Springer, S.** & Knight, K. Building and Implementing a Mobile Health Unit (MHU) in Partnership with a County Hospital Health System. Addiction Health Services Research (AHSR) Annual Conference, New York, New York. Oct 18-20, 2023.

2023: Lu H, Thornhill T, **Springer SA**, Petrakis IL, Gonsalves GS. Buprenorphine in Substance Use Disorder (SUD) Specialty Settings versus Non-SUD Settings: Trial Emulation using the Veterans Health Administration Data. (Accepted poster presentation). Addiction Health Services Research Conference. New York, USA, Oct 18-20, 2023.

2023: Grebla R, Strand L, Zhao X, Zhou S, Keshishian A, Lee J, **Springer S**, McLain M. Variation in Real-World Pharmacologic and Nonpharmacologic Treatment Of Alcohol Use Disorder Among Patients With Common Chronic Medical Conditions. Poster 221. Research Society on Alcohol (RSA)Scientific Meeting, Bellevue, WA, USA. June 24-28, 2023.

2023: **Springer SA**, Seval N, Litwan A, Gopoladas M, Roth P, Levin F, Brady K, Nunes N. Starting Injectable Buprenorphine in Persons Hospitalized with Opioid Use Disorder and Infections; Symposium. American Society of Addiction Medicine (ASAM) 54th Annal Conference, April 13-16, 2023. Washington, D.C.

2023: Ank Nijhawan, Zoe Pulitzer, Brynn Torres, Mark Sanchez, Alysse Schultheis, Cynthia Frank, Richard Colon, Ralph Brooks, Randi Proffit, Maverick Salyards, **Sandra Springer**, Kevin Knight. Indications for PrEP in a Justice-Involved Population: Intersection of substance use and sexual risk *Addressing risk through Community Treatment for Infectious diseases and Opioid use disorder Now among justice-involved populations (ACTION)* [Conference presentation]. 16th Annual Academic & Health Policy Conference on Criminal Justice Health (ACCJH), April 13-14, Raleigh, North Carolina, Oral Presentation.

2023: Proffitt, R., Nijhawan, A., **Springer, S.**, & Knight, K. 2023. Early Lessons Learned from a multisite randomized controlled trial of evaluating methods to improve linkage to HIV prevention and treatment services for persons with opioid and stimulant use involved in the justice system: *Addressing risk through Community Treatment for Infectious diseases and Opioid use disorder Now among justice-involved*

populations (ACTION) [Conference presentation]. 16th Annual Academic & Health Policy Conference on Criminal Justice Health (ACCJH), April 13-14, 2023. Raleigh, North Carolina.

2023: Di Paola A, Farabee D, **Springer SA**. Creation and Validation of the Rapid Opioid and Stimulant Use Disorder Assessment for DSM-5 Criteria. Oral Presentation. Conference presentation]. 16th Annual Academic & Health Policy Conference on Criminal Justice Health (ACCJH), April 13-14, 2023. Raleigh, North Carolina.

2023: Schultheis A, Lancaster M, Santiago S, Muggeo J, **Springer SA**. Peer Navigation and Service Utilization Upon Reentry into the Community Among Justice-involved Persons. Oral Presentation. Conference presentation]. 16th Annual Academic & Health Policy Conference on Criminal Justice Health (ACCJH), April 13-14, 2023. Raleigh, North Carolina.

2023: Parchinski K, Di Paola A, **Springer SA**. Recidivism Among Persons with HIV Receiving Extended-Release Naltrexone. Poster Presentation. Conference presentation]. 16th Annual Academic & Health Policy Conference on Criminal Justice Health (ACCJH), April 13-14, 2023. Raleigh, North Carolina.

2023: DiFiore, E., Sease, T., Proffitt, R., Pankow, J., Di Paola, A., **Springer, S.**, Nijhawan, A., Knight, K. Stigma as a Barrier to Care Among Justice-Involved Individuals Living With or at Risk for HIV and Substance Use Disorder. Poster Presentation at the American Medical Women's Association 108th Annual Meeting, March 23-26, 2023 Philadelphia, Pennsylvania.

2022: Sease, T. B., Villaire, S., Di Paola, A., Sanchez, M., Pulitzer, Z., Hansen, L., Pankow, J., Bennett, A., Nelson, J., Brooks, R., Frank, C., Proffitt, R., Nijhawan, A., **Springer, S.**, & Knight, K. (2022, October 11-13th). Identifying Services Gaps and Needs along the Substance Use, HIV, and HCV Continuum of Care for People in the Justice System: A Mixed Method Approach [Poster Presentation #63558]. Fast Track Cities Conference, October 21-22, 2022, Sevilla, Spain.

2022: Sean Luo (chair); Laura Brandt, **Sandra Springer**, Gabriel Odom (presenters). Application of Predictive Modeling and Pragmatic Trial Big Data in OUD Clinical Practice. Symposium. *Title of Springer talk: Adapting Criminal Justice Treatment to High Needs patients with extended-release naltrexone*. 33rd AAAP (American Academy of Addiction Psychiatry) Annual Meeting and Symposium, December 8-11, 2022, Naples, Florida.

2022: **Sandra A. Springer (chair)**, Frances Levin (Co-Chair). Presenters: Sandra A. Springer, Nikhil Seval, Alain Litwin. Edward Nunes (Discussant). Early Lessons Learned About the Use of Injectable Long-Acting Buprenorphine in Persons Hospitalized with Infections and Opioid Use Disorder. Workshop. 33rd AAAP (American Academy of Addiction Psychiatry) Annual Meeting and Symposium, December 8-11, 2022, Naples, Florida.

2022: Nikhil Seval, Johnathan Nunez, Prerana Roth, Meredith Schade, Michelle Strong, Cynthia A. Frank, Alain H. Litwin, Frances R. Levin, Kathleen T. Brady, Edward Nunes, **Sandra A. Springer** Inpatient Low Dose Transitions from Full Agonist Opioids Including Methadone onto Long-Acting Depot Buprenorphine: Case Series from a Multicenter Clinical Trial. Oral Paper presentation. 33rd AAAP (American Academy of Addiction Psychiatry) Annual Meeting and Symposium, December 8-11, 2022, Naples, Florida.

2022: Manesh Gopaldas, Brent Vander Wyk, Victor Neirinckx, Angela Di Paola, Alain H. Litwin, Kathleen T. Brady, Frances R. Levin, Edward V. Nunes, **Sandra A. Springer**. The Impact of COVID-19 on Overdose Risk and Healthcare-Seeking Behaviors Among Hospitalized Patients with Opioid Use

Disorder, Oral Paper presentation. 33rd AAAP (American Academy of Addiction Psychiatry) Annual Meeting and Symposium, December 8-11, 2022, Naples, Florida.

2022: **Springer SA***, Seval N, Frank C, Roth P, Strong M, Nunez JJ, Schade M, Litwin A Brady KT, Levin FR, Nunes EV. Preliminary Results from A Randomized Controlled Trial of An Integrated Care Model of Infectious Disease Management and Long-Acting Injectable Buprenorphine For Patients Hospitalized With Infections And Opioid Use Disorder. Paper # 458. Accepted Late-Breaker Oral Presentation. 10th International Conference on Health and Hepatitis Care in Substance Users (INHSU). October 19, 2022. Glasgow. Scotland.

2022: Lier A, Vander Wyk B, Di Paola A, **Springer S.** Evaluation of The Impact Of Hiv Diagnosis On The Hepatitis C Virus Care Cascade And Risk Behaviors Among Persons Receiving Medication Treatment For Opioid Use Disorder. Paper #460. Accepted Late Breaker Poster Presentation. 10th International Conference on Health and Hepatitis Care in Substance Users (INHSU). October 19-21, 2022. Glasgow. Scotland.

2022: Lier A, Seval N, Vander Wyk B, Di Paola A, **Springer S.** Maintenance on Extended-Release Naltrexone Is Associated with Reduced Injection Opioid Use Among Justice-Involved Persons with Opioid Use Disorder. Paper #459. Accepted Late Breaker Poster Presentation. 10th International Conference on Health and Hepatitis Care in Substance Users (INHSU). October 19-21, 2022. Glasgow. Scotland.

2022: Di Paola A, Sanchez M, Schultheis A, Brooks R, Frank CA, Pankow J, Villare S, Lehman W, Pulitzer Z, Hansen L, Kuo I, Nijhawan AE, Knight K, & **Springer SA.** Results of a community and justice needs assessment for HIV prevention and treatment and substance use treatment services for persons involved in the justice system. 17th International Conference on HIV Treatment and Prevention Adherence, July 11-13, 2022. Washington, D.C. Oral Presentation, Abstract ID 60130.

2022: Pankow J, Bennett A, Villaire S, Sease T, Lehman W, Pulitzer Z, Hansen L, Frank CA, Di Paola A, Sanchez M, Thomson K, **Springer SA**, Nijhawan AE, & Knight K. The role of patient navigators and mobile health units in behavioral and healthcare services delivery with justice-involved individuals. 17th International Conference on HIV Treatment and Prevention Adherence, July 11-13, 2022. Washington, DC, Oral Presentation, Abstract ID 60672.

2022: Satcher M.F., Saunders EC, Monico LB, **Springer SA**, Farabee D, Gryczynski J, Schwartz RP, Nyaku A, Reeves D, McDonald RD, Lee JD, Marsch LA, Waddell EN. (2022, June 11-15). *The Impact of the COVID-19 Pandemic on the Treatment of Opioid Use Disorder among Populations with Justice Involvement: A Cross-Sectional Study.* [Conference presentation abstract]. 84th Annual Scientific Meeting of the College on Problems of Drug Dependence, Minneapolis, MN, United States.

2022: Lier A, Seval N, Vander Wyk B, Di Paola A, **Springer SA.** Extended-release naltrexone lowers injection use in justice involved persons with HIV (ID 1642). Poster. Conference on Retroviruses and Opportunistic Infections (CROI). Denver, CO. February 2022. *

2022: Collora JA, **Springer SA**, Kluger Y, Ho, Y.C. HIV-1 provirus-host chromatin interactions at the integration site" (id 590). Conference on Retroviruses and Opportunistic Infections (CROI). Denver, CO. February 2022. *

2021: MacNamara K, Biondi B, Hernández-Ramírez R, Taweh N, Grimshaw A, **Springer SA.** Infectious Disease Outcomes among Persons with Opioid Use Disorder Treated with Buprenorphine, Methadone or Extended-Release Naltrexone: A Systematic Review and Meta-Analysis. College on Problems of Drug Dependence (CPDD) Virtual 2021 Conference. June 2021.

2021: Biondi B, VanderWyk B, Shaw A, **Springer SA**. An Evaluation of Factors Associated with Retention on Medication Treatment for Opioid Use Disorder among a Cohort of Persons Seeking Treatment in the Community. College on Problems of Drug Dependence (CPDD) Virtual 2021 Conference. June 2021.

2021: Waddell EN, Baker R, Collins DR, Bialas S, Hartung DM, Hildebran CJ, Korthuis PT, Kunkel LE, Larsen J, Lee JD, **Springer S**, Stack E, Nguyen T, Wisdom J, Meyer D. Reducing Overdose After Release from Incarceration (ROAR): Preliminary Findings from the Pre-Pandemic Cohort. College on Problems of Drug Dependence (CPDD) Virtual 2021 Conference. June 2021.

2021: Biondi B, Frank C, **Springer S**. Gender Differences Among Justice-Involved Persons Living with HIV and Opioid and Alcohol Use Disorders Interested in Extended-Release Naltrexone Treatment" 14th Academic and Health Policy on Conference on Correctional Health. Poster Presentation. Virtual Presentation. April 10, 2021.

2021: Grammatico, M., Moll, AP., Choi, K., **Springer, S.**, Shenoi, SV. HIV Pre-exposure prophylaxis (PrEP) Uptake Among Alcohol Users in Rural South Africa. Poster accepted at 4th HIV Research for Prevention Conference; 2021 January 27 – 28; Cape Town, South Africa.

2020: Grammatico, M., Moll, AP., **Springer, S.**, Choi, K., Shenoi, SV. Pre-exposure prophylaxis (PrEP) short-term retention among heavy alcohol users in rural South Africa. Poster accepted at IDWeek 2020; 2020 October 21-25; Philadelphia, Pennsylvania (Virtual due to COVID19 Pandemic).

2020: Cioe K, Biondi B, Easley R, Simard A, Xheng X, **Springer SA**. A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder. AMERSA conference. October 2020 (Virtual due to COVID19 Pandemic).

2020: Cioe K, Biondi B, Easley R, Simard A, **Springer SA**. A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder. International Conference On Opioids. August 2020 (Virtual due to COVID19 Pandemic).

2020: NIDA's STTR consortium (includes **Springer S**). Association Of Individual And Polysubstance Use, Including Binge Alcohol Use, On Condom Use Behavior In A Multi-Site Cohort. Abstract #757. Research Society on Alcoholism conference (RSA). June 21-24, 2020. (Virtual Conference due to COVID19 pandemic).

2020: Taweh N, Biondi B, **Springer S**. Gender Differences Among Persons with OUD Starting Treatment with Methadone or Buprenorphine. *12th International Women's and Children's Health and Gender (InWomen's) Group* conference. Hollywood, Florida, USA June 19, 2020 (Virtual Due to COVID19 pandemic).

2020: Seval N, Marotta P, Biondi B & **Springer S**. Injection Drug Use Risk Behaviors Among Persons involved in the Criminal Justice System With Opioid Use Disorder: A Secondary Analysis. Accepted Oral Presentation. 13th Academic and Health Policy Conference on Correctional Health, Raleigh, NC. April 2-3, 2020.

2020: Biondi B, Frank C, **Springer S**. Gender Differences Among Justice-Involved Persons Living with HIV and Opioid and Alcohol Use Disorders Interested in Extended-Release Naltrexone Treatment" 13th Academic and Health Policy on Conference on Correctional Health. Poster Presentation. April 2-3, 2020 Raleigh, NC.

2019: **Springer S** & Barocas J, Co-Moderators; Thornton A, Thakarak K, Hurley H & Wurcel A, Symposium Presenters: *Practical Guide to the Infectious Diseases and Opioid Use Disorder Syndemic: Regional Response*. IDWeek 2019 Symposium. Washington, DC. October 2, 2019.

2019: Thakor N & **Springer S**. A novel mathematical simulation to study the effect of naltrexone on CD4 cells, CD8 cells, and HIV viral load. Abstract ID# 564. 81st Annual College on Problems of Drug Dependence (CPDD). San Antonio, TX. June 18, 2019.

2019: Biondi, B & **Springer S**. Change in Risk Behaviors Among Recently Released Prisoners Living with HIV and Substance Use Disorders. Oral Abstract Number: 4050. 12th Annual Academic & Health Policy Conference on Correctional Healthcare. March 21-22, 2019. Las Vegas, NV.

2018: **S. Springer**. Alcohol pharmacotherapies to improve alcohol and HIV treatment outcomes after release from prison for women living with HIV and Alcohol Use Disorders in the United States Criminal Justice System; Part of Invited Speaker for Oral Symposium: Alcohol and HIV: closing interdisciplinary gaps and building research agenda for global interdisciplinary research to improve health and child outcomes. Organizer: Tatiana Balachova, NIAAA. Chair, Kendall Bryant, NIAAA. Speakers Ralph DiClemente, Lynn Matthews, Shirish Barve, Anait Marianian, **Sandra Springer**. 19th Congress of International Society for Biomedical Research on Alcoholism (ISBRA 2018) September 10, 2018 in Kyoto, Japan.

2018: **S Springer**. Medication Assisted Treatment For Alcohol Use Disorder To Improve The HIV Continuum Of Care For Women Involved In The Criminal Justice System; Part of Oral Symposium: ‘Women Hold Up Half The Sky: The Evidence From Global Research On Alcohol And HIV Interventions’. Organizer: Tatiana Balachova, NIAAA and Chair: Wendee Wechsberg. Speakers: **Sandra Springer**, Geetanjaili Chander, Som Bohora, & Deidra Roach (NIAAA). Research Society on Alcoholism (RSA). San Diego, CA, June 19, 2018.

2018: J Wagman, M Matsuzaki, N Gnatienco, LR Metsch, C Del Rio, DJ Feaster, JAC Delaney, X Dong, S Kahana, HM Crane, R Chandler, JC Elliott, F Altice, G Lucas, S Mehta, Y Hirsch-Moverman, W El-Sadr, V Quan, **S Springer**, E Pitpitan, J Tsui, Jh Samet. Associations Between Hazardous Alcohol Use, Antiretroviral Receipt And Viral Suppression In HIV-Positive People Who Inject Drugs In The U.S., India, Russia, Vietnam. Poster Abstract. Research Society on Alcoholism (RSA). San Diego, CA. June 16-20, 2018.

2018: **S Springer**, M Azar, , R Barbour, B Biondi, M Herme, F Altice, A Dipaola. Extended-release Naltrexone Improves viral suppression among HIV+ Prisoners. **Oral** abstract 96. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, March 4-7, 2018.

2017: **S Springer**, R Barbour, MM Azar, M Herme, T Winn, FL Altice, A Di Paola. Results of a Double Blind Placebo Controlled Randomized Trial of Extended-Release Naltrexone Among HIV+ Inmates with Opioid Dependence. Conference and Proceedings on Drug Dependence (CPDD). **Oral** Presentation. Montreal, Canada. June 17-18, 2017. June 20, 2017.

2017: **S Springer**, MM Azar, R Barbour, FL Altice, and A Di Paola. Results of a Double Blind Placebo Controlled Randomized Trial of Extended-Release Naltrexone Among HIV+ Inmates with Alcohol Use Disorders. Conference and Proceedings on Drug Dependence (CPDD). **Late Breaker Oral Presentation**. Montreal, Canada. June 17-18, 2017. June 21, 2017.

2017: Beckwith, I. Kuo, R. Young, R. Fredericksen, L. Brinkley-Rubinstein, W. Cunningham, J. Franks, C. Zawitz, D. Seal, **S. Springer**, K. Christopoulos, J. Lorvick, B. Kruszka, J.A. Delaney, H. Crane, S. Kahana, M.L. Biggs. Similar HIV Care Indicators among HIV-Infected Transgender Women and Cisgender Males: Data from the “Seek, Test, Treat, and Retain” Harmonization Initiative. 12th International Conference on HIV Treatment and Prevention. June 4-6, 2017. Miami, FL. June 3-5.

2017: Cunningham W, Nance R, **Springer S**, Golin C, Kruszka B, Whitney B, Franks J, Lorvick J, Lucas G, Wechsberg W, Clemenzi-Allen A, Crane H, Delaney J. Associations of Self-reported ART Adherence with Viral Load in HIV+ Criminal Justice-Involved Populations. Abstract number 187. 12th International Conference on HIV Treatment and Prevention. June 4-6, 2017. Miami, FL. June 3-5.

2017: Kelsey B. Loeliger, Mary L. Biggs, Rebekah Young, Shoshana Y. Kahana, David W. Seal, Curt G. Beckwith, Irene Kuo, Michael S. Gordon, Lawrence J. Ouellet, William E. Cunningham, Jeremy D. Young, **Sandra A. Springer**. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A Seek, Test, Treat, and Retain Harmonization. Abstract number 2086. 10th Academic and Health Policy on Conference on Correctional Health (Atlanta, GA). March 16-17, 2017.

2016: **Springer S**, Azar M, Barbour R, Altice FL, DiPaola A. Extended-release Naltrexone improves HIV Viral load suppression among HIV+ released prisoners with alcohol use disorders. **Late breaker** poster abstract. 21th International AIDS Conference. Durban, South Africa. July 20, 2016.

2016: **Springer S**, Azar M, Barbour R, Krishnahan A, Altice FL, DiPaola A. Extended-release naltrexone increases time to heavy drinking among HIV+ released prisoners with alcohol use disorders. **Oral** Abstract. 21th International AIDS Conference. Durban, South Africa. July 20, 2016.

2016: Mary-Ellen Mackesy-Amiti, Lauren Strand, Robin Nance, William Cunningham, Elise Riley, Chinazo Cunningham, Chuck Cleland, Lisa Metsch, Daniel Feaster, Carlos del Rio, Bridget Kruszka, **Sandra Springer**. An example of exposure heterogeneity when pooling epidemiologic studies for meta-analysis of antiretroviral medication adherence. Abstract 507. 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management August 25-29, 2016. Dublin, Ireland

2015: Loeliger, KB, Biggs, ML, Seal, DW, Gordon, MS, Beckwith, CG, Kuo I, Young JD, Golin CE, Chandler R, Wechsberg WW, Altice FL, **Springer SA**. Gender Differences in Sexual Risk Behaviors Among HIV-infected and Uninfected persons involved in the U.S. Criminal Justice System: The STTR Harmonization Project. Abstract NO. 1497. 2015 National HIV Prevention Conference. December 6-9, 2015, Atlanta, GA.

2015:**Springer SA**. Drug Treatment as HIV Prevention among Women and Girls who Inject Drugs from a Global Perspective: Progress, Gaps, and Future Direction. New York, NY. JAIDS Special Issue Event. Rethinking the Global Response to the HIV Epidemic Among Women Who Use Drugs: an Urgent Cal to Actions. Columbia School of Social Work. October 30, 2015

2015: **Springer SA**. Prevention of relapse to Opioid use as a means to improve HIV treatment outcomes. 6th Annual Prescription Drug Abuse Symposium, Indianapolis, IN. October 28-29, 2015. Oral presentation.

2015: **Springer SA**, DiPaola A, Altice FL. Acceptability of Extended-Release Naltrexone as a conduit to care for HIV+ Criminal Justice populations. 2015 National Summit on HCV and HIV Diagnosis, Prevention, and Access to Care. June 4-6, 2015. Arlington, VA.

2015: Strand L, Nance R, Chandler R, Cunningham W, Riley E, Mehta S, Altice F, Wechsberg W, Cunningham C, Cleland C & **Springer S**. Initial data harmonization in the STTR HIV Consortium: evaluating the relationship between antiretroviral adherence and substance use. Society for Epidemiologic Research (SER) Annual Meeting. Denver, Co. June 18, 2015. Poster session 5

2015: Lee J, **Springer SA**, Friedman P, Farabee D, Schwartz R, & Chandler R. Opioids, CJS Populations, and Medication Assisted Treatment: Jail, Prison, and Community CJS Clinical Trials. Oral Symposium. 8th Academic and Health Policy Conference on Correctional Health. March 20, 2015. Boston, MA.

- 2015: Krishnan A, DiPaola A, Altice FL, & **Springer SA**. Extended-release naltrexone to reduces relapse to alcohol use for HIV-infected prisoners transitioning to the community. Abstract. 8th Academic and Health Policy Conference on Correctional Health. March 19-20, 2015. Boston, MA
- 2014: **Springer, SA**, Smith D, Nwulia E & Lawson, W. Treating the Triple Whammy: Substance Abuse, Mental Illness and HIV/AIDS. Symposium. Abstract No: 252. 66th American Psychiatric Association (APA) Institute on Psychiatric Services (IPS) Conference. October 30-November 2, 2014. San Francisco, CA.
- 2014: Vagenas P, Zelenev A, Di Paola A, Altice FL, **Springer SA**. Retention in Care Among HIV infected Black Men Who Have Sex with Men Before and After Release from Jail: Results from a Multi-site Study. Abstract #365. 9th International Conference on HIV Treatment and Prevention Adherence; June 8-10 2014; Miami, FL.
- 2014: **Springer SA**, Wohl DA, Gordon MS, Kahana SY, Chandler RK. ^[1]^[SEP]Presentation Title: Seek, Test, Treat, and Retain: Addressing HIV in the Criminal Justice System^[SEP]Presenters. 7th Academic and Health Policy Conference on Correctional Health March 21-22, 2014 in Houston, Texas. Submission ID: 18153
- 2014: **Springer SA**, Taxman F, Mbaba M, Wooditch A, Jones D. Presentation title: Client and Systems Issues: Addressing Special Population Health Needs of Justice-Involved Individuals. 7th Academic and Health Policy Conference on Correctional Health March 21-22, 2014, Houston, Texas. Submission ID: 18190.
- 2014: Meyer J, Cepeda J, Wu J, Trestman R, Altice F, **Springer SA**. Longitudinal Treatment Outcomes in HIV-Infected Prisoners and Influence of Re-Incarceration. Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2014; Boston MA. Poster Abstract: P-W2.
- 2013: **Springer SA**, Gastfriend D, Woody, G, Lee J. Symposium: Medication Assisted Therapy: Adaptability and Durability. International Society of Addiction Medicine, Kuala Lumpur, Malaysia, November 21-23, 2013.
- 2013: **Springer SA**, McCarty D, Lee G, Crevecoeur-MacPhail, D, Chalk M. Oral Symposium: Extended-release Naltrexone: Emerging data on effectiveness and cost-effectiveness. Addiction Health Services Research Meeting, October 23-25, 2013, Portland, Oregon.
- 2013: Di Paola A, Altice FL, **Springer SA**. A DSM-IV Mental Illness Evaluation of a Cohort of HIV Infected Prisoners Transitioning to the Community. Abstract No 16427. 6th Academic and Health Policy Conference on Correctional Health, March 21-22, 2013; Chicago, Illinois.
- 2012: **Springer SA**, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoner. Abstract presentation number WEPE 330. XIX International AIDS Conference (AIDS 2012), Washington, D.C., 22-27 July 2012.
- 2012: Lima V, Spaulding A, Kim B, Stein M, Messina L, Beckwith C, Wong J, Bazerman L, Montaner J, Graf I, Isaei A, Coombs D, Altice F, **Springer S**, Winn T, Herma M, Powers K, Wohl D, Erinoff L, Normand J, Seek Test Treat and Retain Corrections (STTaR Corr) Modeling Group. Modeling the impact of implementing a Seek, Test, Treat, and Retain (STTR) strategy to halt epidemic within the Criminal Justice System (CJS) in different regions in the US. Poster Presentation. Abstract No. THPE105. XIX International AIDS Conference. July 22-27, 2012. Washington, D.C.
- 2012: **Springer SA**. Implementing Extended-Release Naltrexone among Alcohol and Opioid Dependent Released Criminal Justice Populations. Symposium, oral presentation. 2012 SAAS conference and NIATx Summit, June 19-22, 2012. New Orleans, LA.

2012: **Springer SA**. Extended-release Naltrexone for HIV+ released prisoners. Chair and Presenter of Oral Symposium. Research Society on Alcoholism (RSOA) Scientific Meeting in San Francisco CA, June 23-27.

2012: **Springer SA**, Nightingale V, Taxman F, Tangney J. Cross-discipline Treatment Approaches for Mental Health and Substance Related Issues for Offenders. Academic & Health Policy Conference on Correctional Health. Oral symposium presentation. March 22-23, 2012. Atlanta, Georgia.

2012: Normand J, Erinoff L, Volkow N, Spaulding A, Altice F, **Springer SA**, Herme M, Wohl D, Powers K, Beckwith C, Rich J, Lima VD, Nosyk B, Montaner J, Coombs D, Issaei A, Graf I. Modeling the Impact of Implementing a Test and Treat Strategy within the US Criminal Justice System. The 2nd Treatment as Prevention Meeting, Vancouver, Canada. April 2012. Oral Abstract.

2011: Chen NE, Meyer JP, Avery AK, Draine J, Flanigan T, Lincoln TP, Spaulding A, **Springer SA**, Altice FL. Adherence to HIV treatment and care among previously homeless jail detainees; 6th International Conference on HIV Treatment and Prevention Adherence, May 22-24, 2011; Miami Beach FL. Abstract Presentation 69889.

2011: Altice FL, Saber-Tehrani AS, Qui J, Herme M, **Springer SA**. Directly Administered Antiretroviral Therapy (DAART) is Superior to Self-Administered Therapy (SAT) Among Released HIV+ Prisoners: Results from a Randomized Controlled Trial (RCT); 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27-March 2, 2011; Boston MA. Abstract Presentation.

2009: **Springer SA**, Chen S, Altice FL. A Prospective Clinical Trial of Buprenorphine Administered As Relapse-Prevention Treatment For Release HIV-Infected Prisoners. " 4th International Conference on HIV Treatment Adherence; April 5-7, 2009; Miami, FL. Oral Abstract 0237.

2009: **Springer SA**, Chen S, Altice, FL. Depression and Symptomatic Response Among HIV-Infected Drug Users Enrolled in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. 4th International Conference on HIV Treatment Adherence. ; April 5-7, 2009; Miami, FL. Oral Abstract 0239.

2009: Maru Smith-Rohrberg D, Bruce R, Walton M, **Springer SA**, Altice FL. Waning of Virological Benefits Following Directly Administered Antiretroviral Therapy among Drug Users: Results from a Randomized, Controlled Trial. 16th Conference on Retroviruses and Opportunistic Infections (CROI); February 8-11, 2009; Montreal, Canada. Abstract 579.

2003: Altice FL, Mezger J, Bruce D, **Springer S**, Hodges J, Friedland GH. Preliminary Results of a Randomized Trial (RCT) of Modified Enhanced Directly Administered Antiretroviral Therapy (mDAART+) vs. Standard of Care Therapy (SAT): A Model for Administration of ART in Marginalized Populations. Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA); October 9-12, 2003; San Diego, CA. Abstract 655.

2003: **Springer S**, Hodges J, Doros G, Pesanti E, Altice FL. Effectiveness of HAART in HIV-Infected Prisoners. Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA); October 9-12, 2003; San Diego, CA. Abstract 652.

2003: Altice FL, Mezger J, Hodges J, Bruce D, **Springer S**, Friedland GH. Directly observed therapy (DOT) for HIV+ drug users (IUDs). Program and abstracts of the 2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 40.

1994: Teoh SK, Mendelson JH, Mello NK, Eros-Sarnyai M, Skupny A, **Springer SA**. Dopaminergic responsivity and prolactin levels in cocaine and heroin dependent men: A pilot study. NIDA Research

Monograph, Problems of Drug Dependence. Proceedings of the 56th Annual Scientific Meeting, College on Problems of Drug Dependence, (CPDD). 1994.

Professional Service:

Peer Review Groups/Grant Study Sections:

2022: Invited DSMB Member U01 DA046430
(Adam Bisaga, Matisyahu Shulman, PIs)
2021: Invited NIDA R01 reviewer June 28, 2021
2020: Invited NIDA R01 and K08 reviewer November 18, 2020
2020: INVITED K99 GRANT REVIEWER NIDA/ NIAAA JUNE 15, 2020
2020: INVITED AHRQ REVIEWER JUNE 10, 2020
2020: Invited Chair of NIDA Clinical Trial Network (CTN) grant reviews.
2019: Invited DSMB member review committee for NIDA CTN study proposals
2019: Invited Chair of the NIDA Justice Community Opioid Innovation Network (JCOIN)
HEAL grant review
2019: Invited co-chair for NIDA Clinical Trial Network (CTN)Node HEAL grant review
2018: Invited member of review panel Advancing Exceptional Research on HIV/AIDS and
Substance Abuse
2018: K99/K12/T32 Section meeting, Study section reviewer NIDA October 15-1
2018: Invited member of the Interventions to Prevent and Treat Addictions (IPTA) study
section, October 4-5, 2018
2018: Member of K99/K12/T32 Study Section, NIDA
2017: Member of K99/K12/T32 Study Section, NIDA
2016: Invited Reviewer of R18 and R01 Grants for AHRQ
2016: Invited Reviewer of U01 by NIAID
2016: Invited Reviewer of R01 Grants for NIDA
2016: Invited Reviewer of AHQR grant reviews
2016: Invited Chair of R01 STTR Youth grant, NIDA
2016: Invited reviewer K99 grants for NIDA (Spring, Summer, Fall sessions)
2015: Invited reviewer of K99, K12 and T32 Grants for NIDA
2015- Present Standing Member of K99/K12/T32 Study Section, NIDA
2014: Invited Reviewer of R21 & R01 Grants for National Institute of Drug Abuse, (NIDA),
February
2013: Invited Reviewer of R25/T32 Grants for National Institute of Drug Abuse (NIDA),
December
2012: Invited Reviewer of R01 Grants for Center for Scientific Review (CSR),
2012 Invited Reviewer of R01 Grants for National Institute of Drug Abuse (NIDA),
December, November
2012 Invited Reviewer of R01 Grants for National Institute of Drug Abuse (NIDA),
October
2012 Invited Reviewer of R01 Grants for National Institute of Alcoholism and Alcohol
Abuse (NIAAA), July 2012
2011 Invited Reviewer of Grants for National Institute of Drug Abuse (NIDA), February
2011
2009- Present: Center for Interdisciplinary Research on AIDS (CIRA), Core Review Committee

Advisory Boards

2021-Present: Appointed International Antiviral Society–USA (IAS–USA) Antiretroviral
Guidelines Panel Member (December 16, 2021)*

2021-2023: Appointed Committee Member for Guidelines for Withdrawal management in Jails

as part of collaboration between American Society of Addiction Medicine (ASAM), the National Commission on Correctional Health Care (NCCHC) and the Department of Justice /Bureau of Justice Agency (BJA).

- 2021- Present:** Invited Appointed member of American Society of Addiction Medicine (ASAM) Criminal Justice Guideline Committee (CJGC)
- 2021- Present:** Appointed DSMB Member for *NIDA UG3 DA047720 (IND 134996) A Pharmacokinetic Study of Vivitrol in Healthy Participants (GM00191)*. PI Adam Bisaga, M.D., Columbia University
- 2020- Present:** Appointed DSMB Member for NIDA Clinical Trials Network (CTN) 0080: *Medication treatment for Opioid use disorder in expectant Mothers (MOMs): a pragmatic randomized trial comparing two buprenorphine formulations*. Theresa Winhusen, Ph.D, PI, U of Cincinnati College of Medicine.
- 2019-Present:** DSMB member for CDC funded Project ROAR; PI, Elizabeth Waddell, PhD, OHSU.
- 2019-Present:** DSMB member for A Pilot Pharmacokinetic Trial of the O'Neil Long Acting Injectable Naltrexone Implant (Study GM0017). PIs Adam Bisaga, MD & Edward Nunes, MD, Columbia U.
- 2019- Present:** Appointed Member of the NIAAA/NIDA Interagency Work Group on Drinking and Drug Use in Women and Girls
- 2019:** Appointed NIDA Clinical Trials Network (CTN) DSMB member for CTN 001 and 0097. July 22, 2019- September 30 2019.
- 2019 – 2020:** Appointed to the National Academies of Sciences, Engineering, and Medicine's (the Academies) Committee on "Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs"
- 2018 – Present:** Invited member of the American Society of Addiction Medicine's (ASAM) National Practice Guideline Expert Panel for Medication Treatment for OUD
- 2018- Present:** Invited member of the SAMHSA State Targeted Response Technical Assistance (STR-TA) program Provide assistance to clinicians for treating patients with Opioid Use Disorder.
- 2018:** Invited Planning Working Group Member and Moderator for the *National Academies of Sciences, Engineering and Medicine (NASEM) Workshop on Integrating Infectious Disease Considerations with Response to the Opioid Epidemic* convened on March 12-13, 2018. Washington, DC.
http://nationalacademies.org/hmd/Activities/PublicHealth/IntegratingInfectiousDiseaseConsiderationswithResponsetotheOpioidEpidemic/2018_MAR-12.aspx.
- 2017-2020:** Invited Member of the Infectious Disease Society of America (IDSA) and HIVMA Working Group On Infectious Disease Issues In the Opioid Epidemic
- 2017:** Patient Clinical Support Services (PCSS) Medication Assisted Therapy (MAT) Extended-release Naltrexone Protocol

2016-2017: American Society of Addiction Medicine (ASAM). Public Policy for Hepatitis C Infection. Invited member of writing group. October 2016.
https://urldefense.proofpoint.com/v2/url?u=https-3A_www.asam.org_docs_default-2Dsource_public-2Dpolicy-2Dstatements_pdf5b01a9472bc604ca5b7ff000030b21a.pdf-3Fsfvrsn-3D0&d=DwMFAG&c=-dg2m7zWuuDZ0MUcV7Sdqw&r=ZopE7HOKuU2n8SXi_pzFgKRO-ELYdmO9zoe94a6WH9k&m=AQ6RIUCpcrpSBY-Q8QKgMasKr8Yc8xuyHjzG0zSgS2g&s=99gsh42L047R1hCcwGFXeaNYvlrhQPPEUyzxBKdlc04&e

Journal Service:

Editorial Boards:

2022- Present, Invited Editor PLOS ONE (December 8, 2022)
2021 -Present, Invited Editorial Advisory Board, Open Forum of Infectious Diseases
2021- Present, Invited Clinical Infectious Disease Advisory Board Member
2020 - Present, Invited Associate Editor, Contemporary Clinical Trials

Reviewer:

2007-Present: Addiction
Addiction Biology
AIDS
AIDS and Behavior
AIDS Care
Alcoholism Experimental & Clinical Research
American Journal of Drug and Alcohol Abuse
American Journal of Psychiatry (AJP)
American Journal of Public Health (AJPH)
Annals of Internal Medicine
British Medical Journal (BMJ)
BMC ID
BMJ Open
Clinical Infectious Diseases (CID)
Contemporary Clinical Trials
Drug and Alcohol Dependence
HIV Clinical Trials
Infectious Disease Clinics of North America
International Journal of Drug Policy
International J of HIV and STDS
International J of Prison Health
Journal of Acquired Immune Deficiency Syndrome (JAIDS)
Journal of Addiction Medicine (JAM)
Journal of the American Medical Association (JAMA)
Journal of Substance Abuse Treatment (JSAT)
Journal of Women's Health
Open Forum Infectious Disease (OFID)
PLOS ONE
New England Journal of Medicine (NEJM)
The Lancet
The Lancet Infectious Disease
The Lancet HIV

The Lancet Regional Health- The Americas
Substance Use Journal

Professional Service for Professional Organizations:

- 2023- Present: Appointed Committee member of Chronic Conditions Among Women. The National Academies of Science, Engineering and Medicine. May 2023- Present.
- 2022- Present: Appointed committee member: Viaduct and Pew Charitable Trusts: Medicaid standards of care for Opioid Use Disorder in correctional facilities
- 2021-Present: Appointed International Antiviral Society–USA (IAS–USA) Antiretroviral Guidelines Panel Member (December 16, 2021)*
- 2021-Present: Appointed Committee Member for Guidelines for Withdrawal management in Jails as part of collaboration between American Society of Addiction Medicine (ASAM), the National Commission on Correctional Health Care (NCCHC) and the Department of Justice /Bureau of Justice Agency (BJA).
- 2021- Present: Invited Appointed member of American Society of Addiction Medicine (ASAM) Criminal Justice Guideline Committee (CJGC)
- 2021- Present: Appointed DSMB Member for *NIDA UG3 DA047720 (IND 134996) A Pharmacokinetic Study of Vivitrol in Healthy Participants (GM00191)*. PI Adam Bisaga, M.D., Columbia University
- 2020- Present: Appointed DSMB Member for NIDA Clinical Trials Network (CTN) 0080: *Medication treatment for Opioid use disorder in expectant Mothers (MOMs): a pragmatic randomized trial comparing two buprenorphine formulations*. Theresa Winhusen, Ph.D, PI, U of Cincinnati College of Medicine.
- 2019-Present: DSMB member for CDC funded Project ROAR; PI, Elizabeth Waddell, PhD, OHSU.
- 2019-Present: DSMB member for A Pilot Pharmacokinetic Trial of the O’Neil Long Acting Injectable Naltrexone Implant (Study GM0017). PIs Adam Bisaga, MD & Edward Nunes, MD, Columbia U.
- 2019: Appointed NIDA Clinical Trials Network (CTN) DSMB member for CTN 001 and 0097. July 22, 2019- September 30, 2019.
- 2019- Present: Appointed Member of the NIAAA/NIDA Interagency Working Group on Drinking and Drug Use in Women and Girls
- 2019- March2020: Appointed to the National Academies of Sciences, Engineering, and Medicine’s (the Academies) Committee on “Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs
- 2018-2020: Invited member of the American Society of Addiction Medicine (ASAM) National Practice Guideline Expert panel for Medication Treatment for Opioid Use Disorder
- 2018- 9/2020: Vice President, Connecticut Academy of Arts & Sciences (CAAS)
- 2018- Present: Selected Expert as Recovery Consultant for the State Targeted response Technical Assistance Program (STR-TA) Consortium funded by SAMHSA to provide expertise in treatment of opioid use disorders with medications.
- 2017-Present: Invited Member of the IDSA and HIVMA Working Group On Infectious Disease Issues In the Opioid Epidemic
- 2017-Present: Regular member of Conference on Problems of Drug Dependence (CPDD)
- 2014- Present: Co-chair of NIDA’s Seek Test Treat And Retain Committee on HIV Risk Behavior Data Harmonization
- 2010-Present: Invited member of Seek, Test, Treat and Retain Criminal Justice and HIV Modeling Group (STTR CJS), National Institute on Drug Abuse (NIDA/NIH)
- 2009-Present: Center for interdisciplinary Research on AIDS (CIRA), Yale School of Medicine, and Elected Core Research Scientist
- 2006-Present: Member, American Society of Addiction Medicine
- 2003-Present: Member, HIV Medical Association

- 2003-2015: Medical Care and Call service for Infectious Disease Patients in the Connecticut Department of Corrections.
- 2001-Present: Member, Infectious Diseases Society of America

Public Service:

2004-2015 Community Health Care Van, Provided volunteer clinical care, assistance and oversight.

2018- Present Recovery Consultant for the State Targeted response Technical Assistance Program (STR-TA) Consortium funded by SAMHSA to provide expertise in treatment of opioid use disorders with medications.

Bibliography:

Peer-Reviewed Original Research

1. Teoh SK, Sarnyai Z, Mendelson JH, Mello NK, **Springer SA**, Sholar JW, Wapler M, Kuehnle JC, Gelles H. Cocaine effects on pulsatile secretion of ACTH in men. *Journal of Pharmacological Experiments and Theories*. 1994; 270 (3): 1134-8. PMID: 7932162.
2. Levin JM, Holman BL, Mendelson JH, Teoh SK, Garada B, Johnson KA, **Springer SA**. Gender Differences in Cerebral Perfusion in Cocaine Abuse: Technetium-99m-HMPAO SPECT Study of Drug-Abusing Women. *Journal of Nuclear Medicine*. 1994; 35 (12):1902-9. PMID: 7989967.
3. **Springer SA** & Gastfriend DR. A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers. *Journal of Addictive Disorders* 1995; 14(2): 53-66. PMID: 8541360.
4. Altice FL, **Springer SA**, Buitrago, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. *Journal of Urban Health: Bulletin of New York Academy of Medicine* 2003; 80(3): 416-427. PMID: 12930880; PMCID: PMC3455979.
5. Altice FL, Mezger J, Hodges J, Bruce RD, Marinovich A, Walton M, **Springer SA**, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV infected drug users: implications for program replication. *Clinical Infectious Diseases*. 2004; 38: S376-87. PMID: 15156426.
6. **Springer SA**, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. *Clinical Infectious Diseases*. 2004; 38(12):1754-1760. PMID: 15227623.
7. Altice FL, Marinovich A, Khoshnood K, Blankenship KM, **Springer SA**, Selwyn PA. Correlates of HIV infection among incarcerated women: Implications for improving detection of HIV infection. *Journal of Urban Health*. 2005; 82(2):312-26. PMID: 15872190; PMCID: PMC3456574.
8. **Springer SA** & Altice FL. Managing HIV in correctional settings. *Current HIV/AIDS Reports*. 2005; 2:165-170. PMID: 16343373.
9. **Springer SA**, Friedland G, Doros, G, Pesanti E, Altice F. Antiretroviral treatment regimens outcomes among HIV-Infected prisoners. *HIV Clinical Trials*. 2007; 8(4):205-12. PMID: 17720660; PMCID: PMC2409059.
10. Altice FL, Maru D, Bruce RD, **Springer SA**, Friedland G. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-Infected drug users: A prospective, randomized controlled trial. *Clinical Infectious Diseases*. 2007; 45(6): 770-8. PMID: 17712763; PMCID: PMC2693907.
11. Maru, DS, Kozal MJ, Bruce RD, **Springer SA**, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: Results from a randomized, controlled trial. *Journal of the Acquired Immune Deficiency*. 2007;15;46(5):555-63. PMID: 18193497; PMCID: PMC2684061.

12. Maru DS, Bruce RD, Walton M, Mezger JA, **Springer SA**, Shield D, Altice FL. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. *AIDS and Behavior*. 2008; 12(2):284-93. PMID: 18085432; PMCID: PMC2693908.
13. **Springer SA** & Bruce RD. A pilot survey of attitudes and knowledge of opioid substitution therapy for HIV-infected prisoners. *Journal of Opiate Management*. 2008; 4(2): 81-86. PMID: 18557164; PMCID: PMC2476214.
14. Maru DS, Bruce RD, Walton M, **Springer SA**, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: Results from a randomized, controlled trial. *Journal of the Acquired Immune Deficiency*. 2009; 1;50(2):176-81. PMID: 19131891; PMCID: PMC2670996.
15. **Springer SA**, Chen S, Altice FL. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. *AIDS Care*. 2009; 21; 8: 976-983. PMID: 20024753; PMCID: PMC2797133.
16. **Springer SA**, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of Buprenorphine treatment. *Journal of Urban Health*. 2010; 87(4): 592-602. PMID: 20177974; PMCID: PMC2900572.
17. Anand P, **Springer SA**, Copenhaver M, Altice FL. Neurocognitive impairment and HIV risk factors: A reciprocal relationship. *AIDS and Behavior*. 2010; 14(6): 1213-26. PMID: 20232242; PMCID: PMC2906682.
18. Azar MM, **Springer SA**, Meyer JP & Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. *Drug and Alcohol Dependence*; 112:178-193. PMID: 20705402; PMCID: PMC2997193.
19. **Springer SA**, Azar MM, Altice FL. HIV and alcohol dependence: A Call for evidence-based treatments for released prisoners. *American Journal of Drug and Alcohol Abuse*. 2010; 37(1); 12-21. PMID: 21171933; PMCID: PMC3070290.
20. Meyer JP, **Springer SA**, Altice FL. Substance abuse, violence, and HIV in women: A literature review of the syndemic. *Journal of Women's Health*. 2011; 20(7). PMID: 21668380; PMCID: PMC3130513.
21. Chen NE, Meyer JP, **Springer SA**. Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. *Infectious Disease Reports* 2011; 3:e6; 20-29. PMID: 23745166; PMCID: PMC3671603.
22. Meyer JP, Chen NE, **Springer SA**. HIV Treatment in the criminal justice system: Critical knowledge and intervention gaps. *AIDS Research and Treatment*, 2011 680617. Epub 2011 Jul 12. PMID: 21776379; PMCID: PMC3137962.
23. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, Simao M, Hankins C, Schwartlander B, Ridzon R, Bazin B, Williams B, Lo YR, McClure C, Montaner J, Hirschall G, Welte A, End A, Duerr A, Kurth A, del Rio C, Gordon C, Celum CL, Beckwith C, Seal DW, Wohl D, Havlir DV, Mills E, Malitz F, Marks G, Caswell G, Van Cutsem G, Colfax G, Kuo I, Sikazwe I, Neaton JD, Mermin J, Amon J, Rich J, De Cock K, Ouellet LJ, Metsch L, van Deth L, Gardner LI, Santoro MM, Newell ML, Harrington M, Gordon MS, Das M, Ford N, Garg N, Keiser O, Cherutich P, Cohen RM, Chandler R, Lester R, Sheneberger R, Tatoud R, Braithwaite RS, **Springer S**, Fidler SJ, Lynch S, Mehta S, Bärnighausen T, Mastro TD, Miller V, Dukay V, Lima VD, Quan VM, El-Sadr W, O'Brian W, Cunningham WE, Anglaret X, Fleming Y, Wu Z. ART in Prevention of HIV and TB Research Writing Group, Antiretroviral therapy in Prevention of HIV and TB: update on current research efforts. *Current HIV Reports* 2011. 9 (6); 446-69. PMID: 21999779; PMCID: PMC3531820.
24. Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, **Springer SA**, Altice FL. Adherence to HIV treatment and care among previously homeless jail detainees. *AIDS and Behavior*, 2011. Nov 8. PMID: 22065234; PMCID: PMC3325326.
25. **Springer SA**, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. *Clinical Infectious Disease*, 2011. 53(5): 469-479. PMID: 21844030; PMCID: PMC3156144.
26. Saber Tehrani AS, **Springer SA**, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, Study Design and Sample Characteristics of a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy for HIV-infected Prisoners Transitioning to the Community - Potential Conduit to Improved

- HIV Treatment Outcomes. *Contemporary Clinical Trials*. 2012. 33(2):436-44. PMID 22101218; PMCID: PMC3268833.
27. Rich JD, Wohl DA, Beckwith CG, Spaulding A, Lepp NE, Baillargeon J, Gardner A, Avery A, Altice FL, **Springer SA**. Centers for AIDS Research-Collaboration on HIV in Corrections (CFAR-CHIC) Working Group. HIV-related research in correctional populations: Now is the time. *Current HIV/AIDS Reports*. 2011; 8 (4):288-296. PMID: 21904902; PMCID: PMC3208731.
28. **Springer SA**, Dushaj A, Azar MM. The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy among Adult Persons Living with HIV/AIDS: A Systematic Review Article. *AIDS Behav* 2012. [Epub ahead of print] PMID: 22644066; PMCID: PMC3481055.
29. **Springer SA**, Qiu J, Saber-Tehrani, AS, & Altice, FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. *PLoS ONE*. 2012; 7(5): e38335. PMID 22719814; PMCID: PMC3365007.
30. Krishnan A, Wickersham JA, Chitsaz E, **Springer SA**, Jordan AO, Zaller N, Altice FL. Post-release substance abuse outcomes among HIV-infected jail detainees: Results from a multisite study. *AIDS Behavior*. 2012. Nov 11. [Epub ahead of print] PMID: 23142854; PMCID: PMC3600070.
31. Meyer J, Wickersham J, Fu JJ, Brown SE, Sullivan T, **Springer S**, Altice F. Partner Violence and Health among HIV-Infected Jail Detainees. *International Journal of Prisoner Health*. *Int J Prison Health*. 2013; 9(3): 124–141. PMID: 24376468; PMCID: PMC3873166.
32. Chitsaz E, Meyer JP, Krishnan A, **Springer SA**, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-infected Persons Entering Jail. *AIDS and Behavior* 2013 May 15. PMID: 23673792; PMCID: PMC3818019.
33. **Springer SA**, Altice FL, Herme M, & DiPaola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. *Contemporary Clinical Trials*. *Contemp Clin Trials*. 2013 Dec 31;37(2):209-218. PMID: 24384538; PMCID: PMC3992862.
34. Meyer JP, Cepeda J, Wu J, Trestman RL, Altice F, **Springer S**. Optimization of HIV Treatment during Incarceration: Viral Suppression at the Prison Gate. *JAMA Internal Medicine*. 2014 May;174(5):721-9. doi:10.1001/jamainternmed.2014.601. PMID:24687044; PMCID: PMC4074594.
35. Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, **Springer SA**. Corrigendum to ‘An Evaluation of Hepatic Enzyme Elevations Among HIV-Infected Released Prisoners Enrolled in Two Randomized Placebo-Controlled Trials of Extended Release Naltrexone. *Journal of Substance Abuse Treatment*. Published online 13 March 2014 . doi:10.1016/j.jsat.2014.02.008. PMID: 28476270; PMCID: PMC5458355.
36. Di Paola A, Altice FL, Powell ML, Trestman RL & **Springer SA**. A Comparison of Psychiatric Diagnoses Among HIV-Infected Prisoners Receiving Combination Antiretroviral Therapy Transitioning to the Community. *Health and Justice* 2014, 2:11. PMID: 25606368; PMCID: PMC4297667.
37. Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, **Springer SA**. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. *Contemporary Clinical Trials* 39 (2014) 256-268. PMID: 25240704; PMCID: PMC4283549.
38. Meyer JP, Cepeda J, **Springer S**, Wu J, Trestman R, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. *The Lancet HIV*, Early Online Publication, 2014. 1(2):e77-e84. [NIHMS: 636511]. PMID: 25473651; PMCID: PMC4249702.
39. Wickersham JA, Azar MM, Cannon CM, Altice FL & **Springer SA**. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). *Journal of Correctional Health Care*, 2015; 21 (1): 12-26. PMID: 25559628; PMCID: PMC4435561.
40. Lincoln T, Simon-Levine D, Smith J, Donenberg GR, **Springer SA**, Zaller N, Altice FL, Moore K, Jordan AO, Draine J, Desabrais M. Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study. *Journal of Correctional Health Care*, 2015; Apr;21(2):125-39. doi: 10.1177/1078345815574566. PMID: 25788608; PMCID: PMC4433291.
41. **Springer SA**, Larney S, Alam Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: Progress, gaps and

- future directions. *J Acquir Immune Defic Syndr*. 2015 Jun 1;69 Suppl 1:S155-S161. PMID: 25978482; PMCID: PMC4443704.
42. Lima VD, Graf I, Beckwith CG, **Springer SA**, Altice FL, Coombs D, Kim B, Messina L, Montaner JSG, Spaulding A, for the Seek Test Treat and Retain Corrections (STTaR Corr) Modeling Group. The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. *PLoS One*. 2015 May 15;10(5):e0128734. doi: 10.1371/journal.pone.0128734. eCollection 2015. PMID: 25978721; PMCID: PMC4433341.
43. Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordon AO, Teixeira PA, Frew PM, Spaulding AC, **Springer SA**. HIV-infected Men Who Have Sex with Men, Before and After Release from Jail: The Impact of Age and Race, Results from a Multi-Site Study. *AIDS Care*. Accepted June 10, 2015. AC-2015-01-0018.R1. PMID: 26275122; PMCID: PMC4713253.
44. Vagenas P, Azar MM, Copenhaver MM, **Springer SA**, Molina PE, Altice FL. The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review : Alcohol and the HIV Continuum of Care. *Curr HIV/AIDS Rep*. 2015 Dec;12(4):421-36. doi: 10.1007/s11904-015-0285-5. PMID: 26412084; PMCID: PMC4643391.
45. **Springer SA**, Brown SE, Di Paola A, Altice FL. Correlates of Retention on Extended-Release Naltrexone among Persons Living with HIV Infection Transitioning to the Community from the Criminal Justice System. *Drug and Alcohol Dependence*. 2015 Oct 28. pii: S0376-8716(15)01719-6. doi: 10.1016/j.drugalcdep.2015.10.023. PMID: 26560326; PMCID: PMC4675147.
46. Christopher PP, Stein MD, **Springer SA**, Rich JD, Johnson JE, Lidz CW. An exploratory study of therapeutic misconception among incarcerated clinical trial participants. *AJOB Empirical Bioethics*. 2016; 7 (1): 24-30.Epub 2015 Jun 24. PMID: 26709382; PMCID: PMC4687735.
47. Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovich S, **Springer S**, Dvoriak S, Altice FL. Determinants of Willingness to Enroll Into Opioid Agonist Therapy among Opioid Dependent People Who Inject Drugs in Ukraine. *Drug Alcohol Depend*. 2016 Aug 1;165:213-20. doi: 10.1016/j.drugalcdep.2016.06.011. PMID: 27370527; PMCID: PMC5094181.
48. Nance RM, Delaney JA, Golin CE, Wechsberg, WM, Cunningham, C, Altice, F, Christopoulos, K, Knight, K, Quan, V, Gordon, MS, **Springer, S**, Young, J, Crane, PK, Mayer, KH, Mugavero, MJ, Del Rio, C, Kronmal, RA, Crane, HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. *AIDS Care*. 2017 Apr;29(4):464-468. doi: 10.1080/09540121.2016.1263721. PMID: 27910703; PMCID: PMC5291764.
49. Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith C, Kuo I, Gordon MS, Altice FL, Ouellet, LJ, Cunningham W, Young JD, **Springer SA**. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. *AIDS Behav*. 2017 Oct;21(10):2945-2957. doi: 10.1007/s10461-017-1722-9. PMCID: PMC5552433
50. **Springer SA**, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. *Drug Alcohol Depend*. 2017 May 1;174:158-170. doi: 10.1016/j.drugalcdep.2017.01.026. Epub 2017 Mar 10. PMID: 28334661; PMCID: PMC5407009.
51. Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, **Springer SA**, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort Profile: Seek, Test, Treat and Retain United States Criminal Justice Cohort. *Subst Abuse Treat Prev Policy*. 2017 May 16;12(1):24. doi: 10.1186/s13011-017-0107-4. PMID: 28511680; PMCID: PMC5433052.
52. Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovich S, Dvoriak S, **Springer SA**, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. *Drug Alcohol Depend*. 2017 Oct 1;179:213-219. doi: 10.1016/j.drugalcdep.2017.07.010. Epub 2017 Aug 5. PMID: 28806638; PMCID: PMC5599372.
53. Mbaba M, Brown SE, Wooditch A, Kiss M, Murphy A, Kumari S, Taxman F, Altice F, Lawson WB, **Springer SA**. Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users

- under Criminal Justice Supervision. *Subst Use Misuse*. 2018 Jul 29;53(9):1519-1528. doi: 10.1080/10826084.2017.1416400. Epub 2018 Jan 15. PMID: 29333954; PMCID: PMC6432769
54. Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, **Springer SA**. Qualitative Assessment of Attitudes About and Preferences for Extended-Release Naltrexone, a New Pharmacotherapy to Treat Opioid Use Disorders in Ukraine. *Journal of Substance Abuse Treatment*. 2018 Mar; 86:86-93. PMID: 29415856; PMCID: PMC5808584.
55. **Springer SA**, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. *J Acquir Immune Defic Syndr*. 2018 May 1;78(1):43-53. doi: 10.1097/QAI.0000000000001634. PMID: 29373393; PMCID: PMC5889326.
56. **Springer SA**, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial. *J Acquir Immune Defic Syndr*. 2018 Sep 1;79(1):92-100. doi: 10.1097/QAI.0000000000001759. PMID: 29781884; PMCID: PMC6092223.
57. Beckwith CG, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, **Springer SA**, Loeliger KB, Franks J, Christopoulos K, Lorvick J, Kahana SY, Young R, Seal DW, Zawitz C, Delaney JA, Crane HM, Biggs ML. Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. *PLoS One*. 2018 May 22;13(5):e0197730. doi: 10.1371/journal.pone.0197730. PMID: 29787580; PMCID: PMC5963777.
58. **Springer SA**, Korthuis PT, Del Rio C. Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. *Ann Intern Med*. 2019 Apr 2;170(7):509. doi: 10.7326/L19-0042. PMID: 30934074; PMCID: PMC6251491.
59. Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Perez Trejo ME, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, **Springer S**, Chandler R, Kahana S, Crane HM. Reduced use of illicit substances, even without abstinence, is associated with improved depressive symptoms among people living with HIV. *J Acquir Immune Defic Syndr* 2018 Jul 19. doi: 10.1097/QAI.0000000000001803. PMID: 30036277; PMCID: PMC6681811.
60. Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, **Springer SA**. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. *Drug Alcohol Depend*. 2019 Jan 1;194:59-68. doi: 10.1016/j.drugalcdep.2018.10.003. Epub 2018 Oct 23. PMID: 30412898; PMCID: PMC6312501.
61. Fanucchi L, **Springer SA**, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV *Curr HIV/AIDS Rep*. 2019 Feb;16(1):1-6. doi: 10.1007/s11904-019-00436-7. PMID: 30684117; PMCID: PMC6420833.
62. **Springer SA**, Korthuis PT, Del Rio C. Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. Response Letter. *Ann Intern Med*. 2019 Apr 2;170(7):509. doi: 10.7326/L19-0042. PMID: 30934074.
63. Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice FL, Beckwith CG, Chander G, Chandler R, Christopoulos K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, *Kuo I*, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, **Springer S**, Strand L, Taxman F, Young JD, Crane HM. Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. *Clin Infect Dis*. 2020 Feb 14;70(5):867-874. doi: 10.1093/cid/ciz299. PMID: 30994900; PMCID: PMC7319266
64. Makarenko J, Pykalo P; **Springer SA**; Mazhnaya A; Marcus R; Filippovich S; Dvoriak S; Altice FL. Treating Opioid Dependence With Extended-Release Naltrexone (XR-NTX) in Ukraine: Feasibility and

- Three-Month Outcomes. *J Subst Abuse Treat*. 2019 Sep;104:34-41. doi: 10.1016/j.jsat.2019.05.008. Epub 2019 May 10. PMID: 31370983
65. Biondi BE, Frank C, **Springer SA**. Pregnancy, Substance Use, and Research: How do We Protect Women While Increasing Their Participation in Research? *J Addict Med*. 2020 May/Jun;14(3):182-184. doi: 10.1097/ADM.0000000000000565. PMID: 31403523; PMCID: PMC7059864.
 66. Serota D, Baracos JA, **Springer S**. Infectious complications of addiction: A call for a new subspecialty within infectious diseases. *Clin Infect Dis*. 2020 Feb 14;70(5):968-972. doi: 10.1093/cid/ciz804. PMID: 31420651; PMCID: PMC7319263.
 67. Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman F, Altice FL, Delaney J, Crane H, **Springer SA**. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. *BMC Infect Dis*. 2019;19(1):913. Published 2019 Oct 29. doi:10.1186/s12879-019-4443-z. PMID: 31664910; PMCID: PMC6819597
 68. Biondi BE, Frank C, Horn BP, **Springer S**. Reduced Sexual Risk Behaviors among Persons with HIV After Release from the Criminal Justice System. *Open Forum Infect Dis*. 2019 Sep 21;6(10):ofz411. doi: 10.1093/ofid/ofz411. PMID: 31660369; PMCID: PMC6788338.
 69. **Springer SA**, Biondi BE, Frank C, El-Bassel N. A Call to Action to Combat the Opioid Epidemic Among Women. *J Addict Med*. 2020 Sep/Oct;14(5):364-366. doi: 10.1097/ADM.0000000000000622. PMID: 32011410; PMCID: PMC7392801.
 70. Seval N, Eaton E, **Springer SA**. Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases. *Open Forum Infect Dis*. 2019 Dec 24;7(1):ofz539. doi: 10.1093/ofid/ofz539. PMID: 31993454; PMCID: PMC6979000.
 71. **Springer SA**, Rio CD. Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic. *Infect Dis Clin North Am*. 2020;34(3):637-647. doi:10.1016/j.idc.2020.06.015. PMID: 32782106; PMCID: PMC7414693.
 72. **Springer SA**, Rio CD. Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics. *Infect Dis Clin North Am*. 2020;34(3): :xiii-xiv. PMID: 32782107; PMCID: PMC7414777
 73. Seval N, Wurcel A, Gunderson CG, Grimshaw A, **Springer SA**. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review. *Infect Dis Clin North Am*. 2020 Sep;34(3):559-584. doi: 10.1016/j.idc.2020.06.011. PMID: 32782102; PMCID: PMC7437982.
 74. **Springer SA**, Merluzzi AP, Del Rio C. Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics: A Report From the National Academies of Sciences, Engineering, and Medicine. *JAMA*. 2020 Jul 7;324(1):37-38. doi: 10.1001/jama.2020.2559. PMID: 32159771; PMCID: PMC7957328.
 75. Biondi BE, Zheng X, Frank CA, Petrakis I, **Springer SA**. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? *Am J Addict*. 2020;29(4):249-267. doi:10.1111/ajad.13051
 76. JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, **Springer SA**, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. *AIDS*. 2020 Dec 1;34(15):2285-2294. doi: 10.1097/QAD.0000000000002716. PMID: 33048870; PMCID: PMC7951611.
 77. **Springer SA**, Masciotra S, Johnson JA, Campbell S. Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing. *Open Forum Infect Dis*. 2020 Oct 10;7(11):ofaa478. doi: 10.1093/ofid/ofaa478. PMID: 33204760; PMCID: PMC7651562.
 78. Biondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, **Springer SA**. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. *Contemp Clin Trials Commun*. 2021 Jan 6;21:100704. doi: 10.1016/j.conctc.2021.100704. PMID: 33490708; PMCID: PMC7807244.

79. Biondi BE, Frank CA, Forray A, **Springer SA**. Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment. *Subst Abus*. 2021 Mar 22;1-7. doi: 10.1080/08897077.2021.1900984. Epub ahead of print. PMID: 33750285.
80. Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, **Springer SA**. Preventing HIV outbreaks among people who inject drugs in the United States: Plus ça change, plus ça même chose [published online ahead of print, 2020 Aug 20]. *AIDS*. 2020;10.1097/QAD.0000000000002673. doi:10.1097/QAD.0000000000002673 PMID: 32826391; PMCID: PMC7606503.
81. **Springer SA**, Barocas JA, Wurcel A, Nijhawan A, Thakrar K, Lynfield R, Hurley H, Snowden J, Thornton A, Del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda. *J Infect Dis*. 2020 Sep 2;222(Supplement_5):S230-S238. doi: 10.1093/infdis/jiz673. PMID: 32877568; PMCID: PMC7467230.
82. Cioe K, Biondi BE, Easley R, Simard A, Zheng X, **Springer SA**. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. *J Subst Abuse Treat*. 2020 Dec;119:108146. doi: 10.1016/j.jsat.2020.108146. Epub 2020 Sep 22. PMID: 33138929; PMCID: PMC7609980.
83. Wagman JA, Wynn A, Matsuzaki M, Gnatienco N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, **Springer SA**, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. *AIDS*. 2020 Dec 1;34(15):2285-2294. doi: 10.1097/QAD.0000000000002716. PMID: 33048870; PMCID: PMC7951611.
84. Seval N, Frank CA, Litwin AH, Roth P, Schade MA, Pavlicova M, Levin FR, Brady KT, Nunes EV, **Springer SA**. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. *Contemp Clin Trials*. 2021 Apr 7;105:106394. doi: 10.1016/j.cct.2021.106394. Epub ahead of print. PMID: 33838307.
85. Waddell EN, **Springer SA**, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monica L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). *J Subst Abuse Treat*. 2021 Apr 8;108389. doi: 10.1016/j.jsat.2021.108389. Epub ahead of print. PMID: 33865691.
86. Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, **Springer SA**. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. *The International Journal on Drug Policy*. 2021 May;103283. DOI: 10.1016/j.drugpo.2021.103283.
87. McNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimshaw AA, **Springer SA**. A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes, *Open Forum Infectious Diseases*, Volume 8, Issue 8, August 2021, ofab289, <https://doi.org/10.1093/ofid/ofab289>
88. Fredericksen RJ, Whitney BM, Trejo E, Nance RM, Fitzsimmons E, Altice FL, Carrico AW, Cleland CM, Del Rio C, Duerr A, El-Sadr WM, Kahana S, Kuo I, Mayer K, Mehta S, Ouellet LJ, Quan VM, Rich J, Seal DW, **Springer S**, Taxman F, Wechsberg W, Crane HM, Delaney JAC. Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort. *BMC Public Health*. 2021 Nov 4;21(1):2002. doi: 10.1186/s12889-021-12026-7. PMID: 34736425; PMCID: PMC8567631.*
89. Grammatico MA, Moll AP, Choi K, **Springer SA**, Sheno SV. Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South Africa. *J Int AIDS Soc*. 2021 Nov;24(11):e25848. doi: 10.1002/jia2.25848. PMID: 34826363; PMCID: PMC8625837.
90. Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, **Springer SA**. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. *Contemp Clin Trials Commun*. 2021 Nov 11;24:100866. doi: 10.1016/j.conctc.2021.100866. PMID: 34825103; PMCID: PMC8605182.

91. Petrakis I*, **Springer SA* (*co-first author)**, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuíte M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. *Addict Sci Clin Pract.* 2022 Jan 31;17(1):6. doi: 10.1186/s13722-022-00286-6. PMID: 35101115; PMCID: PMC8802273.
92. Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, **Springer SA**. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. *Addict Sci Clin Pract.* 2022 Mar 7;17(1):15. doi: 10.1186/s13722-022-00299-1. PMID: 35255967; PMCID: PMC8899775.
93. **Springer SA**, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK; ACTION Cooperative Group. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. *BMC Infect Dis.* 2022 Apr 15;22(1):380. doi: 10.1186/s12879-022-07354-x. PMID: 35428213; PMCID: PMC9013109.
94. Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, **Springer SA**. Gender differences among persons entering medication treatment for opioid use disorder in the community. *Am J Addict.* 2022 Sep;31(5):390-395. doi: 10.1111/ajad.13304. Epub 2022 Jun 2. PMID: 35652902; PMCID: PMC9463117.
95. Garret R, Cumberland W, Chakravarthy B, **Springer S**, Young S. Qualitative Exploration of the Potential Role of Using Digital Technologies to Increase initiation of Medications for Opioid Use Disorder (MOUD)) ^[L]_[SEP]Manuscript DOI: 10.1080/14659891.2022.2098846 ^[L]_[SEP]Journal of Substance Use. In press. July 14, 2022.
96. Lier AJ, Seval N, Vander Wyk B, Di Paola A, **Springer SA**. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. *J Subst Abuse Treat.* 2022 Nov;142:108852. doi: 10.1016/j.jsat.2022.108852. Epub 2022 Jul 30. Erratum in: *J Subst Use Addict Treat.* 2023 Jul;150:209074. PMID: 35988513; PMCID: PMC9509444.
97. Lazarus JV, Romero D, Kopka CJ, Karim SA, Abu-Raddad LJ, Almeida G, Baptista-Leite R, Barocas JA, Barreto ML, Bar-Yam Y, Bassat Q, Batista C, Bazilian M, Chiou ST, Del Rio C, Dore GJ, Gao GF, Gostin LO, Hellard M, Jimenez JL, Kang G, Lee N, Matičič M, McKee M, Nsanzimana S, Oliu-Barton M, Pradelski B, Pyzik O, Rabin K, Raina S, Rashid SF, Rathe M, Saenz R, Singh S, Trock-Hempler M, Villapol S, Yap P, Binagwaho A, Kamarulzaman A, El-Mohandes A; **COVID-19 Consensus Statement Panel (*Springer part of the COVID19 panel)**. A multinational Delphi consensus to end the COVID-19 public health threat. *Nature.* 2022 Nov;611(7935):332-345. doi: 10.1038/s41586-022-05398-2. Epub 2022 Nov 3. PMID: 36329272; PMCID: PMC9646517.
98. Lier AJ, Vander Wyk B, Di Paola A, **Springer SA**. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. *Open Forum Infect Dis.* 2022 Nov 14;9(11):ofac624. doi: 10.1093/ofid/ofac624. Erratum in: *Open Forum Infect Dis.* 2023 May 16;10(5):ofad260. PMID: 36467300; PMCID: PMC9709708.
99. Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, Lehmann C, **Springer SA**, Sax PE, Thompson MA, Benson CA, Buchbinder SP, Del Rio C, Eron JJ Jr, Günthard HF, Molina JM, Jacobsen DM, Saag MS. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. *JAMA.* 2023 Jan 3;329(1):63-84. doi: 10.1001/jama.2022.22246. PMID: 36454551.
100. Seval N, Nunez J, Roth P, Schade M, Strong M, Frank CA, Litwin AH, Levin FR, Brady KT, Nunes EV, **Springer SA**. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. *J Addict Med.* 2023 Jan 26;10.1097/ADM.0000000000001136. doi: 10.1097/ADM.0000000000001136. Epub ahead of print. PMID: 36701748; PMCID: PMC10368784.
101. Saunders EC, Satcher MF, Monico LB, McDonald RD, **Springer SA**, Farabee D, Gryczynski J, Nyaku A, Reeves D, Kunkel LE, Schultheis AM, Schwartz RP, Lee JD, Marsch LA, Waddell EN. The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional

- study. *Health Justice*. 2022 Dec 19;10(1):35. doi: 10.1186/s40352-022-00199-1. PMID: 36529829; PMCID: PMC9760540.
102. **Springer SA.** Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They Are. *J Gen Intern Med*. 2023 Sep;38(12):2816-2818. doi: 10.1007/s11606-023-08142-2. Epub 2023 Mar 31. PMID: 37002460; PMCID: PMC10506995.
 103. Parchinski K, Di Paola A, Wilson AP, **Springer SA.** The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV. *Drug Alcohol Depend Rep*. 2023 Apr 14;7:100159. doi: 10.1016/j.dadr.2023.100159. PMID: 37159815; PMCID: PMC10163604.
 104. Di Paola A, Farabee D, **Springer SA.** Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non-Clinicians. *Psychiatr Res Clin Pract*. 2023 Aug 15;5(3):78-83. doi: 10.1176/appi.prcp.20230022. PMID: 37711754; PMCID: PMC10499189.
 105. Hill K, Kuo I, Shenoi SV, Desruisseaux MS, **Springer SA.** Integrated Care Models: HIV and Substance Use. *Curr HIV/AIDS Rep*. 2023 Sep 12. doi: 10.1007/s11904-023-00667-9. Epub ahead of print. PMID: 37698755. NIHMS1983971.
 106. Nijhawan AE, Pulitzer Z, Torres B, Noreen N, Schultheis A, Frank C, Colon R, Brooks R, Proffitt R, Pankow J, Bennett A, Salyards M, Kuo I, Knight K, **Springer SA.** HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons. *Emerg Infect Dis*. 2024 Apr;30(13):S68-S74. doi: 10.3201/eid3013.230739. PMID: 38561803; PMCID: PMC10986824.
 107. Lu H, Thornhill T, **Springer SA,** Petrakis IL, Gonsalves GS. Buprenorphine in Substance Use Disorder (SUD) Specialty Settings versus Non-SUD Settings: Trial Emulation using the Veterans Health Administration Data. *Substance Use & Addiction Journal (SAj)*. In Press
 108. Lier A, Shenoi S, Tarfa, A, Kuo I, **Springer SA.** HIV and Substance Use Disorders. *Infectious Disease Clinics of North America*. Special Edition (editors Solomon and Sax). **In press** December 1, 2023.
 109. Tarfa A, Lier A, Shenoi S, **Springer SA.** Considerations when prescribing opioid agonist therapies in people living with HIV. *Expert Review of Clinical Pharmacology*. **In press**
 110. **Springer SA.** Hospitalization with Serious Opioid Injection-Related Infections is A Reachable Moment for Initiation of Medication Treatment of Opioid Use Disorder> Invited Editorial. *JAMA Network Open*. April 12, 2024, IN PRESS.

Chapters, Books, and Reviews

111. **Springer SA.** Fever of Unknown Origin in *Field Guide to Internal Medicine*. Eds, Smith D, Sullivan L & Haye S. Lippincott, Williams & Wilkins. 2004.
112. **Springer SA.** Human Immunodeficiency Virus in *Field Guide to Internal Medicine*. Eds, Smith D, Sullivan L & Haye S. Lippincott, Williams & Wilkins. 2004.
113. **Springer SA.** Alcohol & Illicit Drug Withdrawal/Overdose in *Field Guide to Internal Medicine*. Eds, Smith D, Sullivan L & Haye S. Lippincott, Williams & Wilkins. 2004.
114. Altice FL & **Springer SA.** "Overview of HIV Care and Antiretrovirals." *Clinical Practice in Correctional Medicine*, 2nd edition. Puisis M. ed. Elsevier Inc. San Diego, CA. 2005.
115. Altice FL & **Springer SA.** "Management of HIV/ AIDS in Correctional Settings." *The AIDS Pandemic: Impact on Science and Society*. Mayer K, Pfizer HF. Eds. Elsevier Inc. San Diego, CA. 2005.
116. **Springer SA & Altice FL.** Improving Care for HIV infected Prisoners Released to the Community: An Integrated Health Model in: *Public Health is Public Safety: Improving Public Health through Correctional Health Care*. Greifinger RB (Ed) Springer Inc. New York. 2007.
117. Cepeda J & **Springer SA.** Drug and Alcohol Dependence in the United States Criminal Justice System. *Encyclopedia of Criminology and Criminal Justice*. Binswanger & Taxeman F (Eds). Springer Inco. New York 2013.

118. Copenhaver M, Baldwin P, **Springer SA**, Ezeabogo I, & Altice FL. HIV prevention and care among drug-involved HIV-infected prisoners transitioning to the community. Reentry Planning for Offenders with Mental Disorders: Policy and Practice, Vol. II. Dulgacz, DA (Ed). Civic Research Institute. Kingston, NJ 2013.
119. Nabila El-Bassel, Phillip L. Marotta, MSc, Louisa Gilbert, Elwin Wu, **Sandra Springer**, Dawn Goddard-Eckrich, Timothy Hunt. Integrating treatment for opioid use disorders and HIV services into Primary Care: Solutions for the 21st Century. May 2018.
120. Seval N, Eaton E, **Springer SA**. Inpatient Opioid Use Disorder (OUD) Treatment for the Infectious Disease Physician. In *The Opioid Epidemic and Infectious Diseases* (Edited by Brianna Norton). Elsevier Inc. March 1, 2020.
121. **Springer SA**, Poland C, Sadacharan R. Care People in the Criminal Legal System. In *Addiction Medicine Pocket Guide* (American Society of Addiction Medicine (ASAM)). Editors: Wakeman S, Alvanzo A, & Lee J. Publishers, Wolters Kluwer; New York, NY; 2023.

Invited Editorials and Commentaries

122. **Springer, SA**. Improving healthcare for incarcerated women. *J Womens Health* (Larchmt). 2010 Jan;19(1):13-5. doi: 10.1089/jwh.2009.1786. PMID: 20088653; PMCID: PMC2828190.
123. **Springer SA**. Commentary on Larney (2010): A call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners. *Addiction*. 2010 Feb;105(2):224-5. doi: 10.1111/j.1360-0443.2009.02893.x. PMID: 20078481; PMCID: PMC2825564.
124. **Springer SA**. A Commentary: High rates of depressive symptomatology among injecting drug users in Saskatoon, Canada. *Evidence Based Mental Health*. 2012 Feb; 15(1):9. Doi: 10.1136/ebmh.2011.100199. Epub 2011 Nov 1. PMID: 22044870.
125. **Springer, S**. HCV reinfection is low among persons who use drugs maintained on medication treatment for Opioid Use Disorder. Invited Editorial Commentary. *Clin Infect Dis*. 2019 Jul 26:ciz695. doi: 10.1093/cid/ciz695. Online ahead of print. PMID: 31346595
126. **Springer S**. Aortic Valve Surgery Outcomes Reporting and Implications for Persons who Use Drugs with Infective Endocarditis. Invited Editorial Commentary. *Clin Infect Dis*. 2019 Oct 7:ciz837. doi: 10.1093/cid/ciz837. Online ahead of print. PMID: 31588502
127. **Springer SA & Del Rio C**. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! *Clin Infect Dis*. 2020 Oct. 23;71(7):1723-1725. doi: 10.1093/cid/ciaa111. PMID: 32011653; PMCID: PMC7583407.
128. Del Rio C & **Springer SA**. Hepatitis C in the United States: One Step Forward, Two Steps Back. *Am J Public Health*. 2021 May;111(5):768-769. doi: 10.2105/AJPH.2021.306251. PMID: 33826392; PMCID: PMC8033994.
129. **Springer SA**. Commentary on Murphy et al.: What will it take to prescribe extended-release naltrexone to treat alcohol use disorder? *Addiction*. 2021 Sep 22. doi: 10.1111/add.15668. Epub ahead of print. PMID: 34549844.

Case Reports, Technical Notes, Letters

130. **Springer SA & Altice FL**. Human immunodeficiency virus infection with human granulocyte ehrlichiosis complicated by symptomatic lactic acidosis. *Clinical Infectious Diseases* 2003 Jun 15; 36(12):e162-4. [PMID: 12802782]
131. Altice FL, **Springer SA** & Pesanti E. Reply to Badudieri et al. *Clinical Infectious Diseases* 2004;39.
132. Altice FL, **Springer SA**. DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for non-adherence and use of untested interventions. *Arch Internal Medicine*. 2010; 170(1):109-10. PMID: 20065210; PMCID: PMC2825565.
133. **Springer SA**. Extended-Release Naltrexone for HIV+ Released Prisoners. *Alcoholism Clinical & Experimental Research* 2012. Supplement 36 (6); 342A. No. 156.

Educational Resources:

134. **Springer SA.** Hepatitis B and C Prevention and Treatment in Persons who Use Drugs. Webinar For PCSS MAT training. October 27, 2014. **Revised and Updated October 2017.**
<http://pcssmat.org/education-training/modules/aaap-online-module-hepatitis-c-and-b-prevention-and-treatment-in-persons-who-use-drugs/>
135. **Springer SA.** Monitoring of Liver Function Tests in Patients Receiving Naltrexone or Extended-Release Naltrexone. PCSS Educational Information. October 27, 2014. **Revised and Updated October 2017.** <http://pcssmat.org/new-clinical-guidance-posted-monitoring-of-liver-function-tests-in-patients-receiving-naltrexone-or-extended-release-naltrexone/>
136. **Springer SA.** Advancing Antiretroviral Therapy for HIV: Tailoring a Regimen for the Treatment-Experienced Patient Webinar as part of the **2014 HIV Summit Series: Clinical Challenges in HIV Management: A Two-Part Educational Series. Penn State Hershey College of Medicine.** December 9, 2014. <https://event.webcasts.com/viewer/directLink.jsp?ei=1050240>
137. **Springer SA.** Drug treatment to improve the HIV continuum of care for Women who use drugs: progress, gaps, and future directions. Web-based education. SAMHSA. April 27, 2016
138. **Springer SA, Bisaga A, Training.** PCSSPM. XR-Naltrexone: A Step-by-Step Guide. In: Providers Clinical Support Services (PCSS) Projects AAoAPA, ed. East Providence, Rhode Island, USA2017.
139. **Sandra A. Springer,** Invited Contributor to Substance Abuse and Mental Health Services Administration (SAMHSA), (NIDA). Advances in Non-agonist Therapies. Collaborator. In: U.S. Department of Health and Human Services SAaMSA, Center for Substance Abuse Treatment, ed. Rockville, MD: U.S. DHHS; 2016:1-50.
140. American Society of Addiction Medicine (ASAM). **Sandra A. Springer, MD, invited co-member of writing group.** Policy on Hepatitis C Diagnosis and Treatment among persons who use Drugs. October 2016. https://urldefense.proofpoint.com/v2/url?u=https-3A_www.asam.org_docs_default-2Dsource_public-2Dpolicy-2Dstatements_pdf5b01a9472bc604ca5b7ff000030b21a.pdf-3Fsfvrsn-3D0&d=DwMFAg&c=-dg2m7zWuuDZ0MUcV7Sdqw&r=ZopE7HOKuU2n8SXi_pzFgKRO-ELYdmO9zoe94a6WH9k&m=AQ6RIUCpcrpSBY-Q8QKqMasKr8Yc8xuyHjzG0zSgS2g&s=99gsh42L047R1hCcwGFxYeaNYvlrhQPPEUyzxBKdIc04&e=
141. HIV/HCV Virtual Roundtable. **Springer SA,** Brady K, Litwin A. July 2019. DDK MD Inc.
Link: <https://spaces.hightail.com/receive/NF9g9yPCds>
142. Clinical Care Options (CCO) Education training video. **Springer S & Rammers C.** Benefits of and Need for Integrated Addiction and Infectious Disease Care. December 2019.
<https://www.clinicaloptions.com/hiv/programs/addiction-hcv-hiv>
<https://www.clinicaloptions.com/hiv/programs/addiction-hcv-hiv/podcast/podcast-1>
143. National Academy of Sciences, Engineering and Medicine (NASEM) Consensus Study Report. Opportunities to Improve Opioid Use Disorder and Infectious Disease Services. January 20, 2020.
Sandra A. Springer, MD member of appointed committee
<https://www.nap.edu/read/25626/chapter/1>
144. ASAM's National Practice Guidelines for Treatment of Opioid Use Disorders. April 2020. **Sandra A. Springer, MD member of appointed committee.** https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2
145. Clinical Care Options (CCO) Clinical Thought. Integrating OUD Screening, Diagnosis and Medical Treatment into ID Care. Educational Session. **Sandra A. Springer, MD.** June 25, 2020.
<https://www.clinicaloptions.com/hepatitis/programs/addiction-hcv-hiv/clinicalthought/ct2/page-1>
146. **Course Director. Sandra A. Springer, MD.** Clinical Care Options and American Society of Addiction Medicine (ASAM). Incorporating HIV/HCV Prevention, Screening, and Linkage to Care Into Opioid Use Disorder Treatment Settings. July 2020. https://elearning.asam.org/products/incorporating-hivhcv-prevention-screening-and-linkage-to-care-into-opioid-use-disorder-treatment-settings#tab-product_tab_contributors
147. Opioid Use Disorder Treatment in time of COVID19. PODCAST. **Sandra A. Springer, MD & Michael Frost, MD.** Titan. <https://vimeo.com/438502075> (PW: btk123). August 2020.
148. What's New with the Flu '2020-2021. **Sandra A. Springer, MD.** Video Interview. DKBmed. September 18, 2020.

149. HIV Learning Lab. CME Educational Session. DKBmed, LLC. **Sandra A. Springer, MD**. Webinar. September 10, 2020.
150. Integrating Buprenorphine Treatment Into Infectious Disease Settings. **Sandra A. Springer, MD**. Recorded Educational Program. Opioid Learning Institute and DC Health. September 21, 2020.
151. American Society of Addiction Medicine (ASAM) and the National Association of Drug Court Professionals (NADCP) Pocket Guides for *Treatment Court Clinicians, Non-Clinicians and Treatment Court Participants*. **Invited co-writer, Sandra A. Springer, MD**. September 25, 2020.
152. HIV Treatment: New Guidelines and Evidence to Support Faster ART Initiation. CME Educational Recorded Live Webinar. **Sandra A. Springer, MD** & Marc O Siegel, MD and Melissa Badowski, Pharm D. PRIME and ViiV Healthcare. November 12, 2020.
<https://primeinc.org/programs/hd/80WB203?nopre=1>
153. Raising the Bar in HIV Standards of Care: A 4-Part Video Podcast Series for Providers in Federal & Public Healthcare Settings. Jason M Blaylock, MD, FACP, FIDSA, CTropMed; Gregory S Felzien, MD, AAHIVS; **Sandra A Springer, MD**. Treatment Decision-Making for the Aging Veteran Living with HIV: **Sandra A Springer, MD** & Jason M Blaylock, MD, FACP, FIDSA. PRIME Inc., Sponsored by Gilead Sciences Inc. June 18, 2021. <https://primeinc.org/programs/hd/54PC214?nopre=1>
154. A Treatment Court Clinicians Guide to Treatment of Opioid Use Disorder. American Society of Addiction Medicine (ASAM) and treatment court professionals with addiction treatment expertise from the National Association of Drug Court Professionals (NADCP). Online Pocket guides for Screening, Diagnosis and Treatment of Opioid Use Disorder for Treatment Court Clinicians, Staff and Participants. Online August 19, 2022. **Sandra A. Springer** co-wrote these guidelines.
155. PRIME Educational CME Webinar. HIV and Aging among Veterans webinar. **Sandra A. Springer**, September 7, 2022.
156. Opioid Response Network, New England Regional Webinar. Screening, Diagnosis and Treatment of Opioid Use Disorders. **Sandra A. Springer**, October 13 2022.

Scholarship In Press:

N/A

Media

Sandra A. Springer, MD <https://health.usnews.com/doctors/sandra-springer-221393>

Director of **InSTRIDE** –Integrating Substance Use Treatment Research with Infectious Disease for Everyone <https://medicine.yale.edu/lab/springer/>

1. America's Pharmacist:
<https://digitaleditions.sheridan.com/publication/?m=22640&i=817892&p=28&ver=html5>
2. Yale Medicine Mobile Retail pharmacy <https://medicine.yale.edu/news-article/first-mobile-retail-pharmacy-revolutionizes-health-care-for-hiv-and-opioid-use-disorder/>
3. Yale Daily News: <https://yaledailynews.com/blog/2023/10/13/yale-researchers-help-create-states-first-mobile-pharmacy/>
4. Avant-Garde Award Program for HIV/ AIDS and Substance Use Disorder Research (DP1). Sandra A. Springer Current 2022 Awardee. July 2022. <https://nida.nih.gov/about-nida/organization/offices/hiv-research-program-hrp/avant-garde-award-hivaids-research>
5. *Parts of Connecticut have high rates of drug overdose and death. Will increasing services make a difference?* By Ed Stannard. **Hartford Courant**, Jul 19, 2022. Story about Sandra A. Springer, MD mobile health unit new project for justice involved persons.
<https://www.courant.com/news/connecticut/hc-news-yale-study-prison-connecticut-20220719-oq5snvwtzhazraufad6zazok3y-story.html>
6. Yale School of Medicine. HIV/AIDS Care at Yale. By Ashley P. Taylor. May 18, 2022.
<https://medicine.yale.edu/intmed/news-article/hivaids-care-at-yale/>

7. Rheumatology Advisor. Combine and Conquer: A treatment strategy to combat infections associated with Drug use by Tori Rodriguez, MA, LPC, AHC. May 10, 2022.
<https://click.message.yale.edu/?qs=29b56e26ebf9d5467f11586c9684084e4c52fb59c00df097a7a778c-db345dd26787a8690e7fbc9d99a16e7620465f85d3494405d38c87cb5>
8. Healio News: Combining treatment for opioid use disorder, HIV improves viral suppression, ART adherence (June 25, 2021): https://www.healio.com/news/infectious-disease/20210622/combining-treatment-for-opioid-use-disorder-hiv-improves-viral-suppression-art-adherence?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=1655425680739
9. Coming up short: Court driving NC prisons reform, but expert advice on handling pandemic still rejected (December 16, 2020) <https://carolinapublicpress.org/40730/coming-up-short-court-driving-nc-prisons-reform-but-expert-advice-on-handling-pandemic-still-rejected/>
10. HIV Treatment: New Guidelines and Evidence to Support Faster ART Initiation (December 11, 2020) https://primeinc.org/online/hiv-treatment-new-guidelines-evidence-support-faster-art-initiation?utm_source=primefac&utm_medium=springer&utm_campaign=80WB203
11. IDSA Media Briefing: COVID-19 in Correctional Facilities (December 5, 2020)
<https://www.idsociety.org/es/multimedia/videos/idsa-media-briefing-may-12-2020/>
12. Pharmacotherapy Webinar featuring Dr. Sandra Springer, Yale AIDS Program (November 20, 2020)
<https://www.niaaa.nih.gov/news-events/meetings-events-exhibits/pharmacotherapy-webinar-featuring-dr-sandra-springer-yale-aids-program>
13. \$11.5M Grant Supports Study of Linkage To Community-Based Opioid Addiction and HIV Prevention and Treatment Services for Persons Released From Prison (October 5, 2020)
<https://medicine.yale.edu/lab/springer/news-article/27800/>
14. The ASAM National Practice Guideline 2020 Focused Update Webinar- Individuals in the Criminal Justice System (September 10, 2020) <https://elearning.asam.org/products/the-asam-national-practice-guideline-2020-focused-update-webinar-individuals-in-the-criminal-justice-system>
15. Tweet by CCO Infectious Disease on Twitter (July 24, 2020)
https://twitter.com/CCO_InfDis/status/1286750233511297026
16. Benefits of and Need for Integrated Addiction and Infectious Disease Care (July 9, 2020)
<https://www.clinicaloptions.com/infectious-disease/programs/addiction-hcv-hiv/podcast/podcast-1>
17. Experts expect more prison COVID-19 deaths without more testing (May 18, 2020)
<https://carolinapublicpress.org/30482/experts-expect-more-prison-deaths-covid-19/>
18. ‘One day they came in and told us we had to stay inside because of a virus’ (May 14, 2020)
<https://www.wtsp.com/article/news/investigations/10-investigates/one-day-they-came-in-and-told-us-we-had-to-stay-inside-because-of-a-virus/67-30a076a2-9b07-4a04-b89d-1ab194f5d603>
19. How Can Jails Keep COVID-19 at Bay? ID Specialists Weigh In (May 14, 2020)
<https://www.medpagetoday.com/infectiousdisease/covid19/86492>
20. IDSA Media Briefing: COVID-19 in Correctional Facilities (May 12, 2020)
<https://www.idsociety.org/multimedia/videos/idsa-media-briefing-may-12-2020/>
21. Study shows benefits of treating opioid addiction, HCV at same time (February 14, 2020)
<https://www.healio.com/news/infectious-disease/20200214/study-shows-benefits-of-treating-opioid-addiction-hcv-at-same-time>
22. Introduction and Overview of the Intersection Between Opioid Use Disorder and Infectious Disease (February 6, 2020)
<https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.clinicaloptions.com%2Fhepatitis%2Fprograms%2Faddiction-hcv-hiv%2Fvideo-module%2Fvideo-module&data=02%7C01%7Csandra.springer%40yale.edu%7Cb64334a10f2441f8c51f08d7b022332a%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637171533242244775&sdta=i8pIPCwg7w6AjJt18S2UnVYcJ19qOLZ1xck3nGtKB9A%3D&reserved=0>

23. [Low HIV transmission among recently incarcerated individuals living with HIV and SUDs](https://www.healio.com/news/infectious-disease/20190927/low-hiv-transmission-among-recently-incarcerated-individuals-living-with-hiv-and-suds) (September 29, 2019) <https://www.healio.com/news/infectious-disease/20190927/low-hiv-transmission-among-recently-incarcerated-individuals-living-with-hiv-and-suds>
24. [The Opioid and Associated HIV Epidemics: Why Understanding Sex and Gender Differences in Medication Treatment for OUD Matter](#) (April 30, 2019)
25. [Opioid Use Disorder Should Be Thought of Like an Infectious Disease, Experts Say](https://www.contagionlive.com/view/opioid-use-disorder-should-be-thought-of-like-an-infectious-disease-experts-say) (April 29, 2019) <https://www.contagionlive.com/view/opioid-use-disorder-should-be-thought-of-like-an-infectious-disease-experts-say>
26. [Yale Researcher Awarded \\$40 Million to Study Opioid Addiction Treatments](https://medicine.yale.edu/news-article/19726/) (March 29, 2019) <https://medicine.yale.edu/news-article/19726/>
27. [Researchers win \\$40 million to study opioid addiction](https://yaledailynews.com/blog/2019/03/29/researchers-win-40-million-to-study-opioid-addiction/) (March 29, 2019) <https://yaledailynews.com/blog/2019/03/29/researchers-win-40-million-to-study-opioid-addiction/>
28. [The opioid crisis: 'We still have a lot of work to do'](https://www.msnbc.com/ali-velshi/watch/the-opioid-crisis-we-still-have-a-lot-of-work-to-do-1300537411537) (August 16, 2018) <https://www.msnbc.com/ali-velshi/watch/the-opioid-crisis-we-still-have-a-lot-of-work-to-do-1300537411537>
29. [Integration of Opioid, Infectious Disease Treatment Needed](https://www.empr.com/home/news/integration-of-opioid-infectious-disease-treatment-needed/) (August 15, 2018) <https://www.empr.com/home/news/integration-of-opioid-infectious-disease-treatment-needed/>
30. [Proposed: Screen Patients with Certain Infections for Opioid Addiction](https://www.medpagetoday.com/neurology/opioids/74027) (July 14, 2018) <https://www.medpagetoday.com/neurology/opioids/74027>
31. [Within opioid abuse epidemic, infectious disease epidemic emerges](https://www.reuters.com/article/us-health-opioids-infections/within-opioid-abuse-epidemic-infectious-disease-epidemic-emerges-idUSKBN1K32WM) (July 13, 2018) <https://www.reuters.com/article/us-health-opioids-infections/within-opioid-abuse-epidemic-infectious-disease-epidemic-emerges-idUSKBN1K32WM>
32. [Lessons from HIV epidemic could help address opioid abuse](https://www.healio.com/news/primary-care/20180713/lessons-from-hiv-epidemic-could-help-address-opioid-abuse) (July 13, 2018) <https://www.healio.com/news/primary-care/20180713/lessons-from-hiv-epidemic-could-help-address-opioid-abuse>
33. [Yale study: Drug for opioid, alcohol abuse may help suppress HIV](https://www.middletownpress.com/health/article/Yale-study-Drug-for-opioid-alcohol-abuse-may-12966950.php) (June 4, 2018) <https://www.middletownpress.com/health/article/Yale-study-Drug-for-opioid-alcohol-abuse-may-12966950.php>
34. [Yale study: Drug for opioid alcohol abuse may help suppress HIV](https://www.nhregister.com/news/article/Yale-study-Drug-for-opioid-alcohol-abuse-may-14527724.php) (June 4, 2018) <https://www.nhregister.com/news/article/Yale-study-Drug-for-opioid-alcohol-abuse-may-14527724.php>
35. [This drug to treat alcohol addiction may become the next weapon in the fight against HIV](https://www.lgbtqnation.com/2018/06/drug-treat-alcohol-addiction-may-become-next-weapon-fight-hiv/) (June 11, 2018) <https://www.lgbtqnation.com/2018/06/drug-treat-alcohol-addiction-may-become-next-weapon-fight-hiv/>
36. [Naltrexone improves HIV care in freed inmates](https://www.healio.com/news/infectious-disease/20180312/naltrexone-improves-hiv-care-in-freed-inmates) (March 12, 2018) <https://www.healio.com/news/infectious-disease/20180312/naltrexone-improves-hiv-care-in-freed-inmates>